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It is known that early medical intervention is absolutely vital to improve long term 
outcome of rheumatoid arthritis (RA). However, further research is required to develop 
newer outcome measures that can be objectively and reproducibly used early in the 
course of the disease to predict prognosis. Involvement of bone in RA is common and 
both generalized and peri-articular osteoporosis occur in RA. Hands are generally the 
earliest site to be affected in RA and radiological changes in the hands reflect the 
severity and progression of the disease. The main purpose of this investigation was to 
develop a method of measurement of hand BMC by dual energy x-ray absorptiometry 
(DXA) and to evaluate its potential in monitoring disease progression in patients with RA.
Materials and Methods:
Hand BMC was measured by DXA using a Hologic QDR 1000 machine and a modified 
spine analysis protocol. A customized perspex-aluminium plate was prepared to 
compensate for the smaller amount of soft tissue and bones in hands and the bone to 
soft tissue threshold was altered empirically to get a reasonable definition of the bone 
outline. Nine healthy normal volunteers (3 males, 6 females, age 26-53 years) 
participated in the initial studies on reproducibility and inter-observer variability. Two 
pathology human hand specimens were used to investigate the accuracy. To determine 
the normal ranges of hand BMC, ninety five volunteers (46 males, 49 females, age 20-83 
years) underwent hand BMC measurements on both hands. Thirty seven volunteers 
agreed to be re-scanned to establish the annual rate of change.
We then applied this technique in a cross-sectional study to fifty-six patients (22 males, 
34 females age 25-86 years) with RA of varying severity and duration to study the effect 
of disease on hand BMC, and then in a one year longitudinal study to thirty-nine of the 
original patients to study the annual rate of change. We then carried out a two year 
longitudinal study on hand BMC and biochemical bone markers in forty three patient (17 
males 26 females age 29-77 years) with early RA (disease duration less than two years).
Results:
The reproducibility (CV) of our technique was 1.3% for hand BMD and 2.3% for hand 
BMC. In normal volunteers, the median dominant hand BMC was 46.53 grams in males 
and 30.82 grams in females. It was dependent on the body size and correlated with
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hand volume, weight and height. Unlike the BMC in spine and hip, there was no 
significant correlation between hand BMC and age in volunteers. In the population 
studied, there was no significant difference between the hand BMC of the dominant and 
non-dominant hand either in males or in females. After correcting for body size, males 
had higher hand BMC than females (p=0.01). On annual follow-up, male and pre­
menopausal female volunteers did not lose any hand BMC, but post-menopausal 
females did lose significant amount of hand BMC. In the cross-sectional study on 
patients with established RA (disease duration more than two years), the median 
dominant hand BMC was 42.7 grams in male patients (7.5% reduced, p=0.003, when 
compared to male controls) and 28.4 grams in female patients (7.8% reduced, p=0.01 
when compared to female controls). Over a one year period as a group, there was no 
significant change in parameters of disease activity and in the hand BMC. But the 
changes in hand BMC in individual patients varied from -33% to +8%.
The hand BMC in male patients with early RA (disease duration less than two years) was 
43.5 grams (7% reduction) and 27.7 grams in post-menopausal female patients (8.5% 
reduction) at baseline. In a two year longitudinal study on this cohort, there was a 
progressive loss of hand BMC (compared to baseline -4.65% in the first year and -6.4% 
in the second year) despite significant improvement in other parameters of disease 
activity. This loss of hand BMC correlated with mean CRP over two years and inversely 
with serum osteocalcin over the first year. The collagen cross-link excretion remained 
increased throughout the two year study period.
Conclusions:
We have developed a reproducible method of measurement of hand BMC and have 
successfully applied it to normal volunteers and to patients with RA. This novel 
technique is capable of measuring hand BMC changes in patients with early RA even 
before erosive changes on x-rays are apparent. It therefore has a potential of becoming 





Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease of unknown 
etiology characterized by symmetric polyarthritis mainly affecting small joints of hands 
and feet. The first convincing and clear description of the disease was made by Landre- 
Beauvais in 1800 but the name 'Rheumatoid Arthritis' was coined by Sir Alfred Baring 
Garrod in 1859. As the evidence for the existence of RA before the year 1500 is sparse 
and unconvincing, Boyle and Buchanan postulated that RA is a disease of the modem 
era (Boyle et al 1971). The prevalence and incidence of RA varies between different 
populations and data from North America and Europe show the overall prevalence rate 
of seropositive RA to be 1% in Caucasian adults (Lawrence et al 1994). Women are 
more frequently affected than men at a ratio of 2-3:1 and the prevalence of RA appears 
to increase with age in both sexes (Lawrence et al 1994).
Clinical Manifestations:
The clinical features of RA can be divided in to articular and extra-articular 
manifestations. Symmetric polyarthritis affecting small joints of hands and feet is the 
most dominant articular manifestation which usually follows a course of exacerbation or 
flares and remissions. The natural history of the disease is variable with little joint 
damage and functional impairment in some patients to progressive irreversible joint 
damage and significant disability in others.
Extra-articular manifestations include pericarditis, pleuritis, Felty's syndrome, sub­
cutaneous nodules, vasculitis and anaemia. Osteoporosis of the axial and appendicular 
skeleton is frequently found in patients with RA and has been recognized for a long time 
(Barwell et al 1865). The generalized bone loss in the axial skeleton has been 
suggested as one of the extra-articular manifestations of the disease. Localized peri­
articular osteoporosis on the other hand, is one of the earliest signs of RA on hand x- 
rays (Brook et al 1977). The pathogenesis of this juxta-articular loss of bone is not 
completely understood though locally produced mediators of inflammation are likely to be 
an important cause (Joffe et al 1991). Anti-rheumatic drugs such as methotrexate and 




The current strategies employed in the treatment of RA are directed towards
1. Alleviation of the signs and symptoms of inflammation
2. Prevention of tissue destruction
3. Preservation of function and
4. Reversal of extraarticular phenomena threatening organ functions such as 
mononeuritis, pericarditis and lung fibrosis.
These goals are achieved by a multi-disciplinary team approach with special emphasis 
on patient education, counseling, physiotherapy, occupational therapy and 
pharmacotherapy.
Pharmacotherapy remains the mainstay of the treatment of RA and is divided in ‘first’ 
and ‘second line* drugs. The first line drugs include simple analgesics like paracetamol 
and non-steroidal anti-inflammatory drugs (NSAIDs) e.g. indomethacin, naproxen, 
diclofenac etc. These drugs give immediate relief of pain and inhibit joint inflammation 
and stiffness but do not influence the natural history of the disease.
The ‘second line' drugs are added to the first line agents if the effects of the NSAIDs 
alone are not sufficient in controlling the disease. These drugs e.g. hydroxychloroquine, 
d-penicillamine, sulfasalazine, gold salts, azathioprine, methotrexate and cyclosporin are 
also called ‘disease modifying anti-rheumatic drugs' (DMARDs) or ‘slow acting anti­
rheumatic drugs' (SAARDs). These names suggest that these drugs have the capacity 
to alter the course of the disease and secondly they have a delayed onset of action, 
hence their efficacy can only be evaluated after 3 to 6 months. Corticosteroids such as 
oral prednisolone are also thought to belong to this class of drugs by some authors as 
they can delay development of erosions (Kirwan et al 1995). More recently, new biologic 
agents such as anti TNF-a and IL1 receptor antibody have also been successfully used 
in the treatment of refractory rheumatoid arthritis (Elliot et al 1993).
Prognosis And Disease Modification:
Long term outcome of treating RA can be pessimistic with one study of 20 years follow- 
up showing most patients (54%) either dead (35%) or severely disabled (19%) with only 
18% leading a normal life (Scott et al 1987). The apparent failure to influence the 
prognosis of RA could either be due to use of inappropriate outcome measures in
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monitoring therapy or because of the use of ineffective drugs. It is now clear that if we 
are to avoid such disastrous outcome, early intervention with available treatment 
modalities is absolutely vital. Fries et al (1996) in a 20 year follow-up study showed that 
an early and sustained use of DMARDs led to a 30% reduction in long term disabilities 
as measured by the Health Assessment Questionnaire (HAQ).
However two important questions need to be answered before the early intervention:
1. Which patients should be subjected to these potentially toxic agents, and
2. How early is ‘early intervention'.
To answer these two questions we need to understand the prognosis of the patient as 
the treatment can then be adjusted accordingly. Patients with good overall prognosis 
could be treated with NSAIDs only or with a less effective but less toxic second line 
agent. Patients at worse risk with bad prognosis could be treated at the earliest 
opportunity - even at presentation - with a combination of first and second line agents 
with careful monitoring of response to therapy.
Prognostic Value of Early Features of Rheumatoid Arthritis:
To answer which patients would benefit from early intervention, several studies have 
looked at the features of RA at presentation and its relation to long term prognosis 
(Flemming et al 1976, Hart et al 1977, Emery et al 1992). Those features indicating a 
poor prognosis are female sex, older age at onset, involvement of multiple joints, 
seropositivity, nodule formation, early erosions on x-rays, poor sulfoxidation capacity and 
those with a conserved sequence of the HLA-DR beta allelic third hypervariable region 
(the ‘shared epitope'). Except for the last two features, the remaining factors can be 
easily assessed in routine clinical practice. However, as RA is more common in older 
population and in females, some of these factors lack specificity (e.g. female sex and 
older age at onset) and other important factors lack sensitivity and may not be existent at 
the time of presentation (e.g. presence of nodules and erosions on x-rays). Further 
research into this area is therefore urgently required to develop newer markers that can 
be objectively and reproducibly used early in the course of the disease to predict 
prognosis.
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Process Versus Outcome Variables:
A distinction needs to be made between different types of variables measured in the 
study of RA. Process variables measure the actual disease activity and may vary widely 
during the course of the disease. The example of process variables are early morning 
stiffness, number of swollen and painful joints and laboratory measures of acute phase 
reactants. Outcome variables on the other hand, measure the effect of the disease over 
a defined period of time. Some examples of outcome variables include functional 
outcome as measured by Health Assessment Questionnaire (HAQ) (Fries et al 1980) 
and radiological outcome measured by various methods of scoring x-rays (Larsen et al 
1977, Sharp et al 1985). Ideally the variables measuring process (disease activity) 
should predict the outcome, though multiple measurements of process variables over a 
period of time are needed to achieve this. Outcome variables have their own limitations. 
Their use over a short term is not ideal as they are insensitive to acute change.
Radiological Methods of Measuring Outcome in RA:
Simple joint radiographs in patients with RA measure three aspects: peri-articular 
osteoporosis, loss of joint space and the appearance and progression of erosions. 
Various methods of scoring radiographs (Larsen et al 1977, Sharp et al 1985) are 
however time consuming, need interested and trained observers and are open to 
subjective interpretation. The other major problem afflicting these methods is that they 
are insensitive to the early changes of peri-articular osteoporosis. Furthermore, 
identification of erosions depends on the quality of the radiograph and hand position and 
there is no consensus whether appearance of new erosions is more important than the 
changes in the size of the existing ones.
These so-called ‘gold standard' radiographic outcome measures can therefore become 
‘fools gold' in inexperienced hands (Brower 1990).
Measurement Of Bone Mass In RA:
The advent of measurement of bone mineral density (BMD) by various methods (for 
review see Wahner et al 1994) has opened exciting new possibilities of finding new 
candidates for measuring outcome in RA (Sambrook et al 1986, 1987, Laan et al 1992). 
Dual energy x-ray absorptiometry (DXA) has superseded other methods because of its 
superior precision, accuracy and safety of minimum radiation involved. Unlike the x-ray
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scoring methods, this technique is objective and the results depend minimally on the 
operator.
The rationale for using bone mass measurements as outcome measure in RA are many. 
Apart from the early signs of peri-articular osteoporosis, generalized skeletal effects of 
the disease have been recognized more recently (Verstraetan et al 1986, Sambrook et al 
1986, 1987, Compston et al 1988). Major etiological factors leading to this bone loss 
include the direct effect of inflammatory mediators, decrease in physical activity and 
corticosteroid treatment (Als et al 1985, Bhalla et al 1991, Laan et al 1992). Recent 
longitudinal studies have shown significant generalized bone loss even within the first 
few months of disease in patients with RA that correlated with disease activity (Gough et 
al 1994, Shenstone et al 1994). Bone mass therefore appears to be a variable that 
sensitively reflects the disease activity and severity. With the growing interest in the field 
of osteoporosis, the DXA machines are becoming more easily available in district general 
hospitals, making bone mass measurement in patients with RA a realistic possibility.
Hand Bone Densitometry In RA:
Most studies on skeletal changes in RA have been limited by the available techniques 
and investigate the total body calcium or the bone mass at the lumbar spine, femoral 
neck or the distal radius (Reid et al 1982, Sambrook et al 1986, 1987, Verstraeten et al 
1986, Compston et al 1988, Gough et al 1994, Shenstone et al 1994). However these 
may not be the ideal sites to monitor rheumatoid arthritis. The hand with its multiple 
joints and periarticular bone involvement in RA, combined with the functional effects of 
disease on its usage may act as a site for composite assessment of overall disease 
progression. Longitudinal studies of hand bone mass measurements may therefore be a 
better way to assess the severity and be more sensitive in measuring the progression of 
RA and predicting response to treatment.
Aim And Contents Of This Thesis:
The main purpose of this thesis is to develop a method of measurement of hand bone 
mineral content (BMC) by DXA and to evaluate its potential in monitoring disease 
progression in patients with RA.
The literature on bone metabolism and bone mass measurement in RA is reviewed in the 
next chapter. The development of the method to scan the hand by DXA is then
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described in chapter 3, including the modifications in the Hologic spine protocol needed 
to analyze hand BMC. The accuracy and reproducibility of the new method of hand 
bone densitometry is also described. After the development of the method, we 
investigated the normal ranges of hand BMC as well as the causes of variability in hand 
BMC in healthy male and female volunteers (chapter 4).
We then applied this new method to patients with rheumatoid arthritis of varying duration 
and severity to assess the effects of the disease on hand BMC as well as to investigate 
the changes in hand BMC over a one year period (chapter 5). In a chronic disease like 
rheumatoid arthritis, from the clinician’s and the patient’s point of view the most important 
time to predict prognosis is early in the course of the disease before erosions develop. 
Furthermore, previous radiological studies on the axial skeleton in RA suggest that more 
pronounced changes in bone mass occur early in the course of the disease. We have 
therefore looked in greater detail at the changes in hand bone mass in a cohort of 
patients with ‘early RA' (disease duration less than 2 years) over a period of two years 
and have compared them with biochemical indices of bone metabolism (chapter 6). 
Finally, the discussion and conclusions are offered in chapter 7.
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BONE MASS MEASUREMENT AND BONE METABOLISM 
IN RHEUMATOID ARTHRITIS: A REVIEW
15
INTRODUCTION:
Involvement of bone in rheumatoid arthritis (RA) was first described by Barwell in 1865 
and since then it is known that both generalized and peri-articular osteoporosis occur in 
RA (Kennedy et al 1977). Juxta-articular osteoporosis is one of the earliest radiological 
abnormalities in RA (Brook et al 1977). With the increasing availability of non-invasive 
radiological techniques of measuring bone mass (e.g. single and dual photon 
absorptiometry and dual energy x-ray absorptiometry) several studies have 
demonstrated generalized bone loss in patients with RA (Als et al 1985a, Sambrook et al 
86, 87, 89, Reid et al 1986b, Verstraeten et al 1986, Cooper et al 1988, O'Malley et al 
1989, Butler etal 1991 Laan etal 1992a, 1993a).
The pathogenesis of this localized and generalized bone loss is not clear. Juxta-articular 
bone loss is thought to be due to a local increase in vascularity, direct invasion by 
pannus as well as related to the mediators of inflammatory process in the joint (Joffe et 
al 1991). In the pathogenesis of the generalized bone loss, several factors including 
circulating cytokines produced by the inflammatory process (Kaplan et al 1987, Alwan et 
al 1988, Eastgate et al 1988) and reduced mobility due to functional impairment 
(Fogelman et al 1986, Woolf et al 1991) are proposed as the important etiological 
factors. Various drugs like glucocorticoids, and more recently methotrexate, used in the 
therapy of RA are implicated in the localized and generalized bone loss (Laan et al 
1992b, Preston et al 1993). To try and resolve these issues, bone turnover in RA has 
been studied by new biochemical assays of bone metabolism (Sambrook et al 1985, 
Gevers et al 1986, Weisman et al 1986, Seibel et al 1989, Pietschmann et al 1989) and 
also by bone histomorphometry (Shimizu et al 1985, Van Soesbergen et al 1986, Mellish 
et al 1987, Compston et al 1994). The ends of the spectrum are clear. Patients with 
longstanding destructive and disabling rheumatoid disease have generalized 
osteoporosis (Als et al 1985a) with increased risk of fractures (Hooyman et al 1984) and 
early rheumatoid disease without functional impairment is associated with peri-articular 
osteoporosis (Kennedy et al 1977). There have been controversies on whether all or 
only some patients with RA are affected by generalized osteoporosis, the comparative 
effects of various etiologically agents, the dose of corticosteroids that causes or does not 
cause bone loss and the clinical significance of this (Sambrook et al 1986, Woolf 1991, 
Laan et al 1992a, Bhalla et al 1992). Some in fact have suggested that steroids, by 
reducing the disease activity and improving mobility, stop bone loss (Sambrook et al 
1989).
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This chapter reviews the measurement of appendicular and axial bone mass by 
densitometry, and the assessment of bone metabolism using biochemical markers as 
well as histomorphometry in patients with RA. The important factors in the pathogenesis 
of bone loss in RA are also discussed.
Potential Problems In Interpretation Of Results:
Before comparing different studies, it is important to recognize the potential problems in 
data interpretation. These problems can be related to:
1. Nature of variables used (e.g. Process V Outcome variables)
2. Study design (e.g. Cross-sectional V Longitudinal)
3. Methods and their limitations.
Bone loss in rheumatoid arthritis can be monitored by indicators of disease ‘process' as 
well as indicators of ‘outcome'. Certain biochemical markers of bone turnover (e.g. 
osteocalcin and urinary cross-links) reflect acute changes in bone metabolism and hence 
measure the ‘process' of bone loss. Bone mass in an individual is a product of the 
genetic background and the effect of internal (e.g. hormonal status, presence of RA) and 
external (e.g. diet, exercise) environment. Measurement of bone mass by DXA thus 
reflects these multiple factors as well as many years of disease activity, functional 
capacity and cumulative effect of medication like corticosteroids. Bone mass 
measurement is therefore likely to be an ‘outcome' rather than a ‘process' variable.
Many studies are cross-sectional but this design does not allow for risk factors that may 
have changed over time. Inactive disease at assessment does not exclude the effect of 
previous disease activity on bone mass. One therefore needs to be cautious with claims 
of correlation between measurements of disease activity or biochemical markers of bone 
metabolism and the bone mass.
The third important problem in comparing results of various studies lies with the diverse 
methods and sites of bone density measurement (Table 1) as well as use of various 
assays in the measurement of bone metabolism. The results obtained by different 
methods are not always comparable, for example, the correlation between bone mass at 
an appendicular site such as the distal radius with the bone mass at an axial site such as 
femoral neck or lumbar spine is poor, both in normal and in osteoporotic persons
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(Wahner et al 1994). Also, diseases (e.g. rheumatoid arthritis and osteoarthritis) and 
drugs (e.g. corticosteroids) affect different parts of the skeleton (e.g. axial versus 
appendicular or trabecular versus cortical bone) with varying severity. It may therefore 
be erroneous to claim ‘generalized osteoporosis' looking at appendicular bone mass. 
Careful attention to the methodology is vitally important in interpretation and comparison 
of results.
Biochemical markers of bone turnover reflect changes in the entire skeleton, which may 
not give information about localized osteoporosis in diseases like RA. There is as yet no 
‘gold standard' method for most of the new biochemical assays and different assays may 
give conflicting results in the same individual (Eastell et al 1994). Diurnal variation in 
levels of some of the markers (e. g. urinary collagen cross-links) and effects of various
storage methods (e.g. serum osteocalcin can partially breakdown in peptides at -30°c.) 
also need to be considered when comparing different studies. It is also difficult to 
compare bone formation (serum markers) with bone resorption (usually urine markers). 
Histomorphometry involves bone biopsy, which limits its use in longitudinal studies. 
Biopsies from different parts of the skeleton (peri-articular versus iliac crest) give limited 
site specific information which has a poor precision.
RADIOGRAPHIC MEASUREMENTS OF BONE MASS IN RA:
Plain Radiographs:
Plain radiographs of the peripheral joints (mainly hands and feet) are frequently used for 
diagnosis and for assessment of progression in RA (Scott et al 1985). Out of the three 
diagnostic features of rheumatoid joint damage, namely peri-articular osteoporosis, joint 
space narrowing and erosions, two are directly related to loss of bone. To monitor these 
changes, many radiographic scoring systems have been developed which need single 
PA film of the hands and wrists (Sharp et al 1971 and 1985, Larson et al 1977, Bluhm et 
al 1983). All scoring systems take into account joint space narrowing and osseous 
defects either together (Larsen's method) or separately for individual joints (Sharp’s and 
Bluhm's method).
Over the years, many outcome studies have used these scoring methods to monitor 
disease progression. However many problems still exist with most of these scoring 
systems (for review see Brower 1990) because of the technical and interpretational
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variables involved. The global scoring method of Larsen et al (1977), where a single 
score is given for all the radiological abnormalities in the joint under consideration, and 
the detailed scoring method of Sharp et al (1985), where a separate score is given to 
each radiological abnormality in the joint concerned, have the problem of poor sensitivity 
to monitor change. These methods can be either imprecise and coarse or too 
cumbersome and time consuming. They require interested and trained observers and 
are not good at quantifying early changes before erosions.
Radiogrammetry:
Radiogrammetry (Burnett et al 1960) is a technique of measuring metacarpal bone mass 
using hand x-rays and Vernier calipers. Measurements of inner and outer diameters at 
the midshaft of the right or left second metacarpal is used to calculate the metacarpal 
area and the bone mass. The manual method (Dequeker et al 1976) has a large 
coefficient of variation (Bloom et al 1980) and the automated method (Kalla et al 1989) 
requires a digitizer interfaced with a PC. Using this automated method of 
radiogrammetry, in a study of 12 male and 69 female patients with RA, Kalla et al(1991) 
showed improvement in the metacarpal bone mass in a subgroup of patients (n=32) 
below age 50, with slow acting anti-rheumatic drugs.
The advantages of radiogrammetry include use of comparatively simple equipment with 
ordinary hand x-rays. However it can only be used on metacarpals and needs interested 
observers. DXA has surpassed radiogrammetry as a standard investigation of choice for 
monitoring osteoporosis.
Microfocal Radiography And Magnetic Resonance imaging (MRI):
Radiographic magnification using a special machine with a microfocal x-ray tube is said 
to be more sensitive in detecting erosive disease than is conventional radiography 
(Resnick et al 1989). However positioning is difficult and only a small area can be 
imaged on one film. The use of MRI in evaluating RA is currently in a period of 
development. At present the use of MRI in imaging bone is very limited and its use is 
therefore inappropriate is demonstration and documentation of bony changes (Brower 
1994).
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Bone Densitometry In RA:
Studies on bone mass measurement in RA focus either on the generalized loss of bone 
measured in the lumbar spine or femoral neck or study the local osteopenia in the 
appendicular skeleton like the distal radius or hand. Table 2 summarizes these studies 
and their conclusions. For this review we have separated the studies on axial (and total 
body) bone mass from those on appendicular skeleton in patients with RA.
Bone Densitometry Of The Appendicular Skeleton:
Single photon absorptiometry (SPA) was one of the earliest techniques to become 
commercially available for bone densitometry. Many of the earlier studies used this 
technique to assess the effect of RA on bone mass by measuring distal radius BMD. 
However, there are two main problems in speculating about generalized skeletal 
changes based on bone densitometry results of the distal radius. As explained earlier, 
subsequent studies have shown that in normal volunteers and in patients with 
osteoporosis, the correlation between bone mass at an appendicular site such as the 
distal radius with the bone mass at an axial site such as femoral neck or lumbar spine is 
poor (Wahner et al 1994). In patients with RA, the 'peri-articular' nature of the distal 
radius may also affect the results. Depending on the wrist's direct involvement in the 
rheumatoid process, the changes in the distal radius may be more or less pronounced, 
leading to erroneous conclusions about general skeleton. A recent study (Peel et al 
1994) on total body BMD measurement in patients with RA highlights the differential 
effect of RA on different parts of the skeleton. When compared to age matched 
normals, the patients with RA had 11% lower bone mass in the lumbar spine, though 
23% lower bone mass in the hand. In a cross-sectional study, Als et al (1984) measured 
the distal radius BMD by SPA in 129 patients with RA. They found that all patients had 
lower BMD as compared to normals (84% of normal) and those on oral corticosteroids 
had even further reductions (73% of normal). Verstraeten et al (1986) found reduced 
bone mass at the distal radius in 64 patients with RA than controls though they did not 
find any effect of corticosteroids. In a longitudinal study over two years in 14 patients 
with RA, Sambrook et al (1990) reported trabecular bone loss (6.1% per annum) in distal 
radius when measured by computed tomography densitometer using 125l isotope.
Hand Bone Densitometry:
Hands and feet are generally the earliest sites to be affected in RA (Flemming et al 
1976) and radiological changes in the hands reflect the severity and progression of the
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disease (Fries et al 1986). It is therefore logical to measure the bone densitometry in the 
hands of patients with RA.
Pye et al (1990) devised a method of hand bone densitometry using DXA. They 
modified the lumbar spine software of the Hologic DXA machine and used a perspex 
aluminium plate to compensate for the small soft tissue and bone thickness in hands. In 
70 postmenopausal women with corticosteroid treated RA, Peel et al (1994) showed that 
hand BMD correlated with BMD at other sites. They however could not find any effect of 
disease duration, disability or steroid therapy on hand BMD. In this thesis, I describe our 
experience with this technique in greater details in further chapters.
Bone Densitometry In Axial Skeleton:
Before the advent of dual photon or dual energy x-ray absorptiometry, measurement of 
total body calcium (TBC) by neutron activation analysis gave some idea about the total 
bone mass. Reid et al (1982) measured the TBC by neutron activation analysis in 63 
patients with RA and showed that they had lower TBC than normals. 31 patients who 
had used oral corticosteroids in the dose of 6 mg per day for up to 5 years had a further 
reduction in TBC as compared to those who did not use corticosteroids. In a longitudinal 
study (Reid et al 1986a) they showed that patients lost 3.7% calcium per annum. When 
these patients were divided according to their steroid dose, it was noted that oral 
corticosteroids in a dose of less than or equal to 5 mg per day was protective. Patients 
on this low dose did not lose any TBC whereas patients not taking corticosteroids or 
those taking higher than 5 mg per day, lost significant amount of TBC.
Further studies on axial skeleton in patients taking oral corticosteroids face several 
problems because of the number of factors involved that can potentially influence the 
bone mass. Apart from the possibility that patients receiving oral corticosteroids are 
likely to have more severe disease and they are likely to be more disabled, these studies 
had to account for the steroid dose, daily and cumulative, as well as duration of steroid 
treatment. In a cross-sectional study, Sambrook et al(1986) has studied the effect of 
corticosteroids on bone mass in 84 female patients with RA. 44 patients had taken oral 
corticosteroids in the mean dose of 8 (range 2.5-16.8) mg per day for an average of 7.5 
years. They found that as compared to a control group, there were significant reductions 
in the spinal (9.6%) and femoral neck (12.2%) BMD in patients treated with 
corticosteroids as well as in those who had not received corticosteroids (reductions of 
6.9% in lumbar spine and 8.9% in the femoral neck). The differences between these two
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groups however did not reach statistical significance. They therefore concluded that low 
dose prednisolone was not associated with increased risk of osteoporosis. Further 
cross-sectional and longitudinal studies by the same group (see Table 2) seem to 
confirm this finding. In a cross-sectional study (Sambrook et al 1987) on 111 patients, 
they reported that there was no difference in either the spinal or femoral neck BMD 
between 44 female patients taking a mean daily dose of 8.5 mg prednisolone and 40 
female patients not taking corticosteroids. 12 male patients on a mean daily dose of 
10.3 mg however had significantly lower spinal BMD (exact values not given) when 
compared with 15 others who did not receive oral steroids. On simple or multiple 
regression analysis, the mean daily dose, the total cumulative dose and the duration of 
therapy with prednisolone did not correlate with the lumbar spine or femoral neck BMD. 
Laan et al (1992b) on the other hand, have reported completely opposite results using 
QCT to measure spinal BMD. In a cross-sectional study of 74 patients with RA, they 
found that 30 patients using oral corticosteroids (mean 7 mg per day for 6 years) had 
31% reduction in the trabecular BMD and 37% reduction in the cortical BMD in the spine 
compared to those who did not use them. In a further double-blind placebo controlled 
prospective study they found that prednisolone 7.5 mg per day for 20 weeks led to a 
partially reversible mean bone loss of 8.2% in the trabecular bone of the lumbar spine 
(Laan et al 1993b). After discontinuation of the therapy and within 24 weeks, these 
patients regained 5.3%. Bone mass was not lost in 20 patients who did not use oral 
prednisolone over this period.
The apparent failure to demonstrate the detrimental effect of corticosteroids on the bone 
mass in patients with RA in various studies by Sambrook et al is difficult to explain. 
Close scrutiny of the results show that patients taking oral CS in most of these studies 
did have lower bone mass as compared to their non-user counterparts, though this 
difference failed to reach statistical significance. One possible explanation could be that 
DPA, the technique used by Sambrook et al, is not as sensitive as DXA or QCT - 
techniques used in later studies by Laan et al. QCT can further separate trabecular and 
cortical bone in the spine and gives a true volumetric bone density as opposed to Areal 
density in DPA. QCT is therefore more accurate than DPA.
Disease duration appears to be an important determinant of bone loss in RA. It is known 
that the natural history of radiological progression in RA is one of an initial rapid rate of 
damage followed by a gradual reduction in the speed of progression (Sharp et al 1985). 
Two recent longitudinal studies (Gough et al 1994b, Shenstone et al 1994), both using 
DXA as the measurement technique, showed that patients with RA lose lumbar spine
22
BMD mainly in the early part of their disease. Gough et al studied 148 patients over 3 
years period and found that the annual rate of loss of BMD in the lumbar spine was 0.2% 
for males and 1.3% for females. When the patient population was divided according to 
their disease duration, female patients with early RA (disease duration < 1 year) were 
found to have lost 2.5% (no results given for early RA males). Shenstone et al (1994) 
found that 16 patients with disease duration of < 6 months lost 3.9% femoral neck BMD 
compared to 0.2% loss in 51 patients with longer disease duration. The low sensitivity of 
the DPA technique to measure change in BMD may also explain findings of another 
longitudinal study (Sambrook et al 1990) which found no significant reduction in the 
lumbar spine bone mass over two years in 17 female patients with early RA (mean 
disease duration 1.2 years) as compared to 18 age matched controls. These female 
patients however lost significant amount of distal radial trabecular bone (11.1% in the 
first year and 1.4% in the second year), although both wrist joints were affected by 
rheumatoid process in all patients.
CONCLUSIONS ON BONE DENSITOMETRY STUDIES IN PATIENTS WITH RA:
1. Patients with RA have lower bone mass as compared to normals in appendicular and 
axial skeleton.
2. Longitudinal studies show that the predominant loss of bone mass occurs early 
(within the first year) after the disease onset.
3. Oral corticosteroids more than 5 mg per day are associated with significant loss of 
bone mass. The effect of corticosteroid doses less than or equal to 5 mg per day is 
unclear.
BIOCHEMICAL MARKERS OF BONE TURNOVER IN RA:
Bone is a metabolically active living tissue undergoing constant remodeling to maintain 
its structural integrity. Bone remodeling occurs in discreet remodeling units, where a 
cavity on the bone surface is eroded by osteoclasts. After a quiescent phase, 
osteoblasts replace an equivalent amount of bone. During bone resorption, constituents 
of bone matrix, mainly collagen, find their way into the circulation and then are excreted 
in the urine through the kidneys. Markers of bone resorption include plasma tartarate 
resistant acid phosphatase, urinary hydroxyproline, pyridinoline and deoxy-pyridinoline 
which are the breakdown products of collagen cross-links (Adachi 1991). Osteoblasts
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produce alkaline phosphatase and osteocalcin, the best known markers for bone 
formation. However, as explained above, there are no gold standard assays available as 
yet and the accuracy and precision between different assays within and between 
laboratories can be considerable (Eastell 1994).
In the last ten years many studies have investigated the usefulness of these markers in 
monitoring the bone changes in RA (Sambrook et al 1985, Weisman et al 1986, Seibel et 
al 1989, Pietschmann et al 1989, Marhoffer et al 1991, Kollerup et al 1994). Table 3 
summarizes the studies discussed in this review.
Biochemical Markers Of Bone Formation:
Serum total alkaline phosphatase has been a readily available biochemical test for many 
years. Apart from bone; liver, placenta and intestine also produce alkaline phosphatase 
isoenzymes (Peel et al 1992). The bone isoenzyme is secreted by osteoblast and its 
measurement is therefore a marker of bone formation. Unfortunately, levels are only 
elevated when bone turnover is very high as in Paget's disease and correlation with high, 
normal or low bone turnover in osteoporosis is poor (Adachi et al 1991). Total alkaline 
phosphatase is found to be raised in patients with RA (Weisman et al 1986, Verstraeten 
et al 1986), though studies on bone specific alkaline phosphatase in RA are not 
available.
Osteocalcin or bone GLA protein (BGP) is a vitamin K dependent non-collagenous 
protein in adult bone (Eastell 1994) produced by osteoblasts. Studies in patients with RA 
have demonstrated variable osteocalcin (OC) levels. Sambrook et al (1985) studied 17 
female patients with early RA (Disease duration mean 1 year). They found no difference 
in the serum OC levels in early RA patients and controls. They however did not give any 
information about use of corticosteroids by patients in this study, though this factor could 
influence serum OC levels (Weisman et al 1986). Weisman et al (1986) showed that in 
81 patients with RA, only 38 patients on oral corticosteroids had significantly reduced 
serum OC levels, whereas the steroid non-users had normal OC levels. This finding was 
later confirmed by Ekenstam et al (1986) who showed that 20 mg of oral prednisolone for 
one week is sufficient to cause a reversible reduction in osteocalcin levels. In their study, 
36 patients with RA and 23 patients with sero-negative spondyloarthropathy had 
significantly low levels of OC even before taking oral corticosteroids. They therefore 
concluded that inflammatory arthritis leads to reduced bone turnover and bone formation 
is further reduced by oral corticosteroids.
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Two further studies however showed raised OC levels in patients with RA (Magaro et al 
1989, Marhoffer et al 1991) which were found to correlate with the disease activity. 
Magaro et al found that in 42 patients, those with active RA had 82% higher OC levels 
than patients with inactive RA and Marhoffer et al demonstrated increased levels of OC 
in older patients (age > 65 years) with new onset RA. These patients however had more 
active disease (as defined by raised ESR) and over one year, the disease activity and 
serum OC both dropped.
Biochemical Markers Of Bone Resorption:
Studies on markers of bone resorption such as pyridinoline and deoxy-pyridinoline show 
more uniform results (see table 3). Pyridinoline (PYD) is the main cross-link between the 
collagen fibrils in cartilage and the most abundant cross-link in bone. Deoxy-pyridinoline 
(DPD) however is bone specific, being derived from type 1 collagen in bone and is not 
found in cartilage. There is considerable diumal variation in the rate of cross-link 
excretion (Peel et al 1992) and it is necessary to collect the urine samples in a uniform 
manner, at the same time of the day. A study by Robins et al (1986) showed 
significantly high levels of PYD excretion in 11 patients with RA compared with 20 
patients with OA. No information is however given about use of corticosteroids, 
menopausal status of the patients as well as the timing of urine collection. Seibel et al 
(1989) et al showed that both PYD and DPD excretion in urine was significantly raised in 
RA, but urinary PYD levels, which is a marker of cartilage and bone degradation, 
correlated with clinical measures of joint involvement (Lansbury joint index, pain score 
and number of joints involved) as well as biochemical variables of inflammatory activity 
(CRP and ESR). Black et al (1989) and Gough et al (1994a) have also shown that 
patients with active disease have higher urinary PYD excretion.
DPD which is a bone specific marker, is also found to be raised in patients with RA 
though it does not correlate with disease activity (Seibel et al 1989, Black et al 1989, 
Gough et al 1994a).
Hydroxyproline, another marker of collagen breakdown is found in many types of 
collagen apart from bone. Its excretion is affected by collagen breakdown in the skin, 
tendons, blood vessels etc. and it is also released during activation of the complement 
cascade as a breakdown product of C1q. This is an important confounding factor in the 
inflammatory arthropathies. Hydroxyproline excretion is also affected by dietary intake of 
gelatin, necessitating collection of fasting urine (Ubelhart et al 1990). Tartrate resistant
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acid phosphatase (TRAP) is another marker of bone resorption (Eastell 1994). However 
at present the assay system of TRAP is either indirect or non-specific and the lability of 
the enzyme does not allow reliable measurements on frozen samples (Adachi 1991).
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CONCLUSIONS ON BIOCHEMICAL MARKERS OF BONE TURNOVER IN RA:
1. Markers of bone formation give conflicting results in patients with RA. It is not clear 
whether the osteoporosis in RA is secondary to reduced rate of bone formation or 
whether the rate of bone formation is raised in RA, though not sufficient enough to 
keep pace with the rate of resorption.
2. Markers of bone resorption show more uniform results with significant increase in 
patients with RA as compared to controls. Patients with active disease have higher 
levels than patients with non-active disease.
BONE HISTOLOGY AND HISTOMORPHOMETRY IN RA:
Bone histology has been studied in RA by either iliac crest biopsies (representing 
generalized changes in the skeleton) or by a sample of bone taken from an operation 
site (usually representing peri-articular bone changes). The invasive nature limits its use 
in longitudinal studies and despite increasing sophistication, the methods have poor 
precision (Eastell 1994).
Wordsworth et al (1984) found evidence of osteoporosis in 10 out of 25 consecutive in­
patients with RA on histological grounds, judged by a reduction in number and thinning 
of trabeculae. The bone biopsies were either taken from iliac crest or from the operation 
site. 14 patients had taken corticosteroids in a dose less than or equal to 10 mg per day 
for up to 24 years. The dietary intake of vitamin D was found to be well below the 
recommended dose in all 25 patients, but there were no histological changes of 
osteomalacia. Mellish et al (1987) studied 48 patients of rheumatoid arthritis none of 
whom had received corticosteroids. They compared the iliac crest trabecular bone 
histology with healthy controls matched for age and sex. The evidence of significant 
trabecular thinning was noted in female patients only. 2 studies by Compston et al 
(1989, 1994) show significant reduction in the eroded perimeter, mean and maximum 
eroded depth and cavity area in patients with non-steroid treated RA. They therefore 
concluded that there is reduced bone formation and low bone turnover in RA as 
compared to healthy controls.
27
Shimuzu et al (1985) on the other hand found exactly opposite results on biopsies from 
juxta-articular bone removed during joint surgery. 20 areas from 12 patients with RA 
were studied and compared with 14 areas from 6 OA patients. 25% of the RA patients 
had taken low dose oral corticosteroids (< 4 mg per day). They found increased bone 
formation as suggested by the increase in the percent of active osteoid surface as well 
as increase in bone resorption as evidenced by increase in percent resorptive surface 
and number of osteoclasts. They therefore concluded that there is increased turnover of 
juxta-articular bone in RA. This apparent discrepancy in the findings of these two 
investigators could be partly explained by the different sites used to obtain bone biopsies 
in these studies. Shimuzu et al studied the peri-articular bone changes as opposed to 
Compston et al, who studied generalized bone changes by iliac crest biopsies.
CONCLUSION ON BONE HISTOMORPHOMETRY IN RA:
It is possible that the peri-articular osteopenia in RA is related to increased bone turnover 
locally, whereas the generalized osteoporosis could be due to a global negative 
remodeling balance.
DETERMINANTS OF BONE MASS IN PATIENTS WITH RA:
Determinants of bone mass have been sought by either calculating correlation 
coefficients between bone mass and a single suspected determinant or by multivariate 
techniques (Sambrook et al 1987, Laan et al 1993a). The former method is of limited 
value since bone mass in patients with RA is under multifactorial influence.
Sex And Menopausal Status:
There has been no uniform effect of sex on differences in bone density in RA and 
controls. In a cross-sectional study, O'Malley et al (1989) et al found a reduction in 
spinal BMD in male patients with RA compared to normals whereas the female patients 
showed more pronounced reductions in femoral neck compared to normals. Laan et al 
(1993a) found both male and female patients with RA had reduced bone mass as 
compared to sex-matched normals to more or less same extent. The study of Als et al 
(1985b) looked at the effect of menopausal state and oral corticosteroids (mean dose 8 
mg) in 97 patients with RA. They found that only in pre-menopausal patients was the 
bone mass significantly affected by corticosteroid treatment. In post-menopausal RA
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patients, the bone loss resulting from menopause and the disease itself, was not 
accelerated by oral corticosteroids. Butler et al (1991) on the other hand found that the 
adverse effects of RA on bone mass are accentuated in the post-menopausal state.
Disease Duration:
Disease duration seems to be an important factor to be considered when studying the 
effect of RA on bone mass. Two recent studies by Gough et al (1994b) and Shenstone 
et al (1994) have confirmed that the deleterious effect of RA occurs mainly in the first 
year of the disease. There were significant differences in the rate of loss of bone 
between patients with disease duration of less than 1 year and those with disease 
duration of more than 1 year. In the study by Shenstone et al, patients with disease 
duration of less than 6 months lost 3.9% femoral neck bone density compared to only
0.2% loss in the remainder of cohort in 67 patients with RA.
Disease Activity:
Cross-sectional study design is not suitable to assess the effect of disease activity on 
bone mass. Several longitudinal studies have shown that patients with high disease 
activity lose more bone density than those with inactive disease. The disease activity is 
however measured differently in various studies. Shenstone et al (1994) used the ‘Stoke 
Index* (Davis et al 1990) which is a composite algorithm incorporating joint count, 
duration of early morning stiffness, ESR, Ritchie index and CRP, and found that the 
lumbar spine BMD changes correlated with the initial Stoke Index but not the mean 
Stoke Indices. Gough et al (1994b) stratified their patients into those with CRP of < 20 
and those with CRP of > 20 mg/dl. Patients with active disease showed significantly 
greater BMD losses at the femoral neck, Ward's triangle and lumbar spine compared to 
patients with inactive disease. In a longitudinal study Laan et al (1993a) used several 
measures of disease activity and found that the mean ESR in 6 months before BMD 
measurement was negatively associated with the BMD in the hip and in Wards triangle. 
Other parameters of disease activity did not show any correlation with BMD.
Biochemical indices of bone metabolism have also been shown to be raised in active 
disease. Raised serum osteocalcin levels (cross sectional study by Magaro et al 1989, 
longitudinal study by Marhoffer et al 1991) and increased urinary excretion of PYD in 
patients with active disease (Gough et al 1994a) have been described. In the study by 
Gough et al, urinary PYD levels (measured only once within the first three months of the 
study) correlated with disease activity (mean of four CRP values measured at entry, 3, 6
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and 12 months) and also with loss of BMD in the femoral neck (measured twice, one 
year apart). This study design is obviously not ideal and it therefore reduces the impact 
of the conclusion that disease activity leads to high bone turnover and consequent bone 
loss. As the biochemical markers reflect changes in entire skeleton, it is not possible to 
know whether this accelerated bone turnover is limited to juxta-articular sites as 
suggested by the histomorphometric studies by Shimizu et al (1985).
Reduced Mobility:
It is known that the level of weight bearing activity is an important determinant of bone 
mass and patients of RA may have reduced general mobility secondary to their disease. 
Sambrook et al (1987) found that reduced physical activity is an important factor in axial 
bone loss in RA. They use the Framingham activity index (Kannel et al 1979) and found 
that in a multiple linear regression analysis, the association of physical activity persisted 
with the femoral BMD but not with the lumbar spine BMD. Parameters of disease activity 
were however not included amongst the variables considered in this analysis. Functional 
capacity evaluated either by Steinbrocker classification or health assessment 
questionnaire is a better and more objective way of assessing physical activity. Gough 
et al (1994b) stratified their patients in to those with HAQ scores of > 8 (HAQ index of > 
1) and those with HAQ score of < 8 (HAQ index of < 1). The more disabled patients 
(HAQ > 8) had significantly greater loss of bone at the lumbar spine, femoral neck and 
Wards triangle. They however do not make it clear whether this effect of functional 
incapacity is independent of disease activity or not. In a longitudinal study, Laan et al 
(1993a) found that the mean HAQ score in the 18 months before BMD measurement 
was negatively associated with BMD in hip only. This was independent of the disease 
duration and the mean disease activity measured by ESR. In a cross-sectional study by 
Black et al (1989), urinary PYD levels correlated inversely with grip strength in 19 
patients with RA, indicating that patients with reduced upper limb function (and perhaps 
mobility) have increased bone resorption.
CYTOKINE PRODUCTION IN RA AND THEIR EFFECT ON BONE:
The adult human bone maintains its strength as a result of continuous cellular activity of 
bone resorption and bone formation. The activities of these cells are closely regulated 
and follow a well defined complex sequence termed the bone remodeling cycle (for 
review see MacDonald et al 1993). This requires both site and cell specific signals 
capable of initiating and promoting the recruitment and proliferation of appropriate cells
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at the appropriate time. This is mediated through cytokines, which are biologically active 
glycoproteins produced by monocytes, macrophages and T lymphocytes. Over the last 
decade, a large evidence is accumulated defining roles of different cytokines in the 
control of bone cell activity (MacDonald et al 1992). We will first describe the role of 
cytokines in the control of bone remodeling cycle and then describe the evidence 
suggesting that abnormal cytokine production may be relevant in the pathogenesis of 
rheumatoid bone disease.
Cytokines And Bone Resorption:
Cytokines acting on bone resorption can be divided into two main groups:
1. Cytokines that stimulate bone resorption: Interleukin 1 (IL-1) and Tumour necrosis 
factor alfa (TNFa).
2. Cytokines that inhibit bone resorption: Interferon gamma (IFNy) & Interleukin 4 (IL-4).
IL-1 remains the most potent cytokine that leads to proliferation and differentiation of 
osteoclast precursors to osteoclasts. It has a stimulatory action on mature osteoclast 
activity. Both these effects of IL-1 lead to significant bone resorption at a very small 
concentration. TNFa has an action very similar to that of IL-1. It acts as a growth factor 
for osteoclast precursors which are from the monocyte - macrophage lineage 
(MacDonald et al 1992). The action of IL-1 and TNFa is thought to be synergistic on 
osteoclasts. Three other cytokines namely, Granulocyte macrophage colony stimulating 
factor (GM-CSF), Macrophage colony stimulating factor (M-CSF) and Interleukin 6 (IL-6) 
are thought to be "permissive" cytokines. They help in bone resorption by maintaining 
adequate numbers of early osteoclasts precursors on which TNFa and IL-1 act 
(McDonald et al 1992).
Termination of osteoclast activity is also thought to be regulated by two cytokines. IFNy 
decreases the number of osteoclasts by reducing the recruitment of osteoclasts 
precursors rather than by having a direct inhibitory effect on mature osteoclasts 
(MacDonald et al 1992). IL-4 also inhibits bone resorption though the mechanism of its 
action remains unknown.
Cytokines And Bone Formation:
In the bone remodeling sequence, bone formation is divided into two stages:
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1. Recruitment and differentiation of osteoblasts
2. Bone matrix production and mineralization 
Cytokines are known to act on both these phases.
IL1 and TNFa, which stimulate osteoclast formation and activity as explained above, also 
have a stimulatory effect on osteoblast proliferation. Once the osteoblasts have 
matured, these two cytokines have inhibitory effect on them. One possible explanation 
for these paradoxical actions is that IL1 and TNFa provide the osteoblasts for 
subsequent phase of bone formation after they have initiated the resorptive phase of 
bone remodeling.
The second group includes transforming growth factor beta (TGFp), insulin like growth 
factor 1 and 2 (IGF1, IGF2) and bone morphogenetic proteins (BMP). These agents 
stimulate both, osteoblast precursor proliferation as well as mature osteoblast function.
In a healthy steady state actions of osteoblasts and osteoclasts are kept in check by all 
these cytokines.
Cytokine Production In RA:
Cytokines can be classified in to three groups according to their role in inflammatory 
arthritis like RA.
1. Pro-inflammatory cytokines
2. Regulatory cytokines produced by T lymphocytes
3. Anti-inflammatory cytokines
Major cytokines in the first group include TNFa, IL1 and IL6. These are produced in 
large amounts by monocytes, macrophages and T lymphocytes, the cells actively 
involved in rheumatoid inflammation. High levels of pro-inflammatory cytokines are 
produced in rheumatoid synovitis (Saxne et al 1988, Miossec et al 1986). The major 
targets for these cytokines are blood vessels, synovium, cartilage and bones. They lead 
to proliferation and neo-vascularisation of the rheumatoid synovium and also lead to 
proliferation and hypertrophy of the synovial cells. They have been known to cause
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expression of adhesion molecules and pro-inflammatory cell migration in the synovium. 
As explained above, these cytokines stimulate bone resorption and osteoporosis in RA.
The regulatory cytokines produced by T lymphocytes namely IL2, IL4, IL5 and INFy are 
thought to play a balancing role in the destruction and repair activity in RA, though 
studies on these cytokines give contradictory results (Miossec et al 1992). More recently 
the concept of inhibitory cytokines (anti-inflammatory cytokines) controlling the extent of 
inflammatory response has been introduced (Miossec et al 1992). IL4 and GM-CSF 
increase monocyte differentiation which reduces production of TNFa, IL1 and IL6, the 
pro-inflammatory cytokines. IL4 and GM-CSF are therefore anti-inflammatory cytokines. 
IL1 receptor antagonist (IL1 RA) is produced by monocytes and it blocks IL1 attachment 
to its receptor acting as a specific antagonist. It therefore acts as another anti­
inflammatory cytokine and is being actively investigated for its possible therapeutic role 
in RA.
FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS:
Apart from the underlying osteoporosis, patients with RA have an increased risk of falls 
secondary to the functional impairment (Tinetti et al 1988). A population based study 
from Mayo Clinic (Hooyman et al 1984) identified 388 women who were followed up over 
a 25 years period (4902 person years). They showed that the relative risk of hip 
fractures in patients with RA was 1.5. Univariate analysis indicated that the increased 
risk of fractures was associated with increasing age, earlier age at diagnosis, disability, 
impaired ambulation, steroid use and thin stature. Obese patients and those who were 
using estrogen had decreased risk of fractures. In multivariate analysis only aging, 
impaired ambulation and thin stature were identified as independent risk factors. The 
type of fractures in the study were proximal femur, proximal humerus, pelvis, distal 
forearm and vertebrae. The relative risk for pelvic fractures was the highest (RR=2.56). 
In another retrospective study of 395 patients with RA, Michel et al (1991) by multivariate 
analysis identified use of corticosteroid in women and prior diagnosis of osteoporosis as 
important risk factors. Among patients taking 5 mg or more of prednisolone, female sex 
strongly predicted fractures and the 5 year probability of having a fracture was 34%. 
Male sex, absence of osteoporosis and patients taking less than 5 mg of prednisolone 
were low risk groups. Insufficiency fractures occur when normal stresses are placed on 
weakened bones. Stress fractures of the pelvis in RA are widely reported in the
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literature (Isdale et al 1993, Peh et al 1993 and Fam et al 1983). Female sex, 
postmenopausal status, steroid treatment and poor mobility are risk factors for these 
type of fractures (Isdale et al 1993). The characteristic sites of these fractures is the 
body of the pubis (parasymphysial) and the sacral ala (Peh et al 1993). Plain x-ray of 
the pelvis is often not helpful whereas Technetium 99 bone scan is the most sensitive 
method of detecting stress fractures (Peh et al 1993).
TREATMENT OF OSTEOPOROSIS IN RHEUMATOID ARTHRITIS:
Comparatively few studies as yet are available discussing the therapeutic measures to 
prevent osteoporosis in RA and no studies have looked at treatment modalities to reduce 
rate of fractures in RA.
There could be two possible approaches to the treatment of osteoporosis in RA:
1. To control the disease activity effectively by a) pharmaceuticals and b) newer 
biological agents such as IL1 RA, anti TNFa etc.
2. Use of 'bone active' agents such as calcium and vitamin D, hormone replacement 
therapy (HRT) and bisphosphonates.
Effect Of Disease Control On Bone Mass In RA:
In a prospective study of metacarpal bone mass measured by radiogrammetry (Kalla et 
al 1991), patients aged 50 or less either stopped losing or gained metacarpal bone mass 
when treated with slow acting anti rheumatoid drugs (SAARD). Patients aged over 50 
years however continued to lose bone though the rate of loss of bone was reduced with 
this treatment. As SAARD are known to control disease activity this positive effect on 
the bone density was most probably related to suppression of the disease rather than 
the positive effect of SAARD on bone itself. Apart from this paper the overall experience 
with SAARD is not very encouraging. In a prospective study by Reid et al (1986) gold or 
d-penicillamine was able to suppress the disease clinically though these patients still lost 
4.3% total body calcium, which was not different from patients treated with NSAIDs 
alone.
Methotrexate (MTX) is being widely used in the treatment of RA but its bone toxicity is 
not widely publicized. Experiments in rats have shown that even short term use of MTX
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can diminish bone formation rates by 60% with a resultant reduction in trabecular bone 
volume by 27% (Friedlaender et al 1984). This finding was later confirmed by May et al 
(1994) who demonstrated that prolonged MTX administration in rats leads to osteopenia 
by suppression of osteoblastic activity and enhancement of osteoclastic recruitment. In 
a recent paper Bologna et al (1994) showed that after intramuscular administration, high 
MTX concentrations were found in the cortical and trabecular bone of RA patients. 
Histomorphometric analysis on two adults being treated with MTX for psoriasis and RA 
showed low osteoid formation and low resorption activity (Preston et al 1993). 
Methotrexate osteopathy is therefore an additional factor which needs to be considered 
in the treatment of RA. Use of newer agents such as IL1 receptor antagonist and anti- 
TNFa are being actively investigated in the treatment of RA and their effect on bone 
mass in RA would be interesting to note.
Use Of Bone Active Agents In RA:
Calcium alone has been shown to be ineffective in preventing loss of bone in patients 
with RA (Reid et al 1986a, Hall et al 1994). In postmenopausal women, estrogen 
therapy has been shown to preserve the spinal and femoral neck BMD in patients with 
RA (Hall et al 1994). In a prospective study of 200 postmenopausal women with RA, 
Hall et al (1994) showed that the patients receiving HRT improved spinal bone density by 
2.2% as opposed to patients treated with calcium alone, who lost lumbar spine BMD by 
1.1% over 2 years. Differences between the treatment groups were not significant for 
the femoral neck. In 21 HRT treated patients taking corticosteroids the bone mass both 
in lumbar spine and femoral neck was preserved over the 2 year period. In a similar 
double blind prospective study on 40 postmenopausal women with active RA (van der 
Brink et al 1993), significant improvement in the lumbar spine and femoral neck BMD 
was noticed in the estrogen group compared with the placebo group.
Bisphosphonates, which are strong inhibitors of bone resorption, have recently been 
tried in the treatment of RA. Eggelmeijaer et al (1994) found a disease suppressive 
effect of a single infusion of pamidronate in 30 patients with active RA. The ESR and C 
reactive protein levels improved significantly in patients treated with 40 mg of 
pamidronate, though parameters of bone metabolism (serum osteocalcin and serum 
alkaline phosphatase) remained unchanged. The pamidronate infusions were however 
associated with rapid and sustained fall in urinary calcium and creatinine ratio. Bone 
densitometry studies on patients with RA treated with bisphosphonates are needed.
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Future studies on newer agents in the treatment of RA should include bone mass
measurement as one of the outcome measures. This will clarify which agents have the
capacity to control the disease and also prevent bone loss in rheumatoid arthritis.
CONCLUSIONS:
1. Patients with RA lose axial and peri-articular bone mass predominantly in the first 
year of disease.
2. The bone loss in RA is multi-factorial, but disease activity and use of oral 
corticosteroids in a dose of more than or equal to 5 mg. are two most important 
determinants.
3. Osteoporosis in RA leads to increased risk of fractures.
4. There are no proven therapies as yet available to prevent bone loss in RA but on the 
basis of existing studies, early and stricter control of rheumatoid activity and use of 
HRT in post-menopausal women with RA is recommended.
5. Future drug trials in the treatment of RA should consider including hand bone mass 
measurement as one of the outcome measures.
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Legends For The Tables:
Table 1: Methods of bone density measurement used in studies on patients with RA. 
Table 2: Studies on bone mass measurement in RA.
CS = Corticosteroids, LS = Lumbar spine, FN = Femoral neck, HAQ = Health 
assessment questionnaire.
Table 3: Studies on biochemical markers of bone metabolism.
RIA = Radioimmunoassay, OC = Osteocalcin, CS = Corticosteroids, OA = Osteoarthritis.
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Table 1:
METHOD* NAA SPA DPA DXA QCT









Precision f 2 - 5% 1 - 2% 2 - 4% 1 - 2% 2 - 5%
Accuracy $ 5-10% 5% 5-10% 4 - 8% 5 - 20%
Radiation dose 
(mrem)
2000 - 5000 5-10 5 1 -3 100-400
* NAA = neutron activation analysis, SPA = single photon absorptiometry,
DPA = dual photon absorptiometry, DXA - dual energy X-ray absorptiometry,
QCT = quantitative computed tomography 
t  Precision is defined as the coefficient of variation for repeated measurements,
i  Accuracy is defined as the coefficient of variation between the result of the
measurement involved and that of a reference method (for example 
measurement of ashed weight).
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31 used oral CS
6 mg 4.6 years
24 received CS 
2.5 mg -10  mg/day
28 received CS 
9 mg/day 4.7 years
44 received CS 










































Cross sectional ! Steroids users LS 90.4 
FN 87.8
Steroid non-users: LS 93.1
FN 91.1
(These differences are not 
significant)
Patients had lower TBC. Oral 
corticosteroids lead to further 
loss of TBC.
Patients had lower bone 
mass in the distal radius. 
Those on CS had further 
reduction in bone mass.
Very contradictory results. 
Patients not on steroids in 
fact had higher spinal BMD 
than controls. Only those on 
oral CS had lower spinal 
BMD than controls, but this 
difference was because of 
longer disease duration 
rather than steroids
themselves. Despite this, 
there was an increased 
incidence of fractures
(16.3%) in steroid than non 
steroid group (3.6%).
Female patients had reduced 
BMD in spine & hip compared 
to controls. Low dose 
prednisolone was not 
associated with increased 
risk of osteoporosis.
Reid 1986 
Clin Rh 1986; 
3:372-378
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30 received CS 
5.7 mg 4.7 years
56 received CS 
9 mg/day 6.8 years
22 received CS 
8.2 mg/day 10 years
15 received CS 













Patients had lower TBC and 
they lost 3.7% calcium per 
annum. 11 patients with 
psoriatic arthritis had normal 












Patients had lower TBC. Pts 
on oral CS £ 5mg per day did 
not lose further Calcium but 
those on CS > 5 mg and 
those not taking CS lost 2.3% 
& 4% Calcium/year. Low 
dose CS have pro-tective role 




Cross sectional No figures given but BMD at 
both sites significantly reduced 
in pts compared to controls (P< 
0.001) for both sexes.
Patients had reduced BMD in 
spine & hip. Low dose 
prednisolone (8mg) did not 
affect bone loss. By multiple 
regression analysis, steroid 
dose or duration did not 











Only those on oral steroids 
had significantly lower spinal 
BMD than controls. All 
patients had lower Estrone 
and Androgen levels than 
controls. Oral steroids 











Patients had significantly low 
BMD in spine & hip compared 
to controls. Low dose 
prednisolone (6mg/day) was 















Cross sectional Female Lumbar Spine: 95 
Female Femoral Neck: 80
Male Lumbar Spine: 86 
Male Femoral Neck: 88
Patients had lower BMD in 
spine & hip. There was a 
good correlation between 
DPA & DXA results.
Sambrook 1990 














Distal radius: 6.1% annual loss 
in pts with RA. No loss in 
controls. No change in spite 
BMD in pts or controls.
Rapid trabecular bone loss 
occurs in distal radius in pts 
with RA. Not so in controls. 
No change in LS and mid 





38 57.1 All post­
menopausal
13.2 Median II 10 received CS 






No figures given. Steroid users 
lost 0.5% BMD/yr from Spine. 
Steroid non-users and those on 
HRT did not lose Spinal BMD. 
All lost FN BMD.
All patients lost hip BMD but 
only those on oral steroids 
lost spinal BMD. Estrogen 
supplement protected against 
spinal bone loss but not 









0.61 30 received CS 
7 mg/day 6 years
QCT Spine Cross sectional No comparison with normals 
available but pts on CS had 
34% lower BMD in spine than 
those without CS.
Long term oral CS in a dose 
of £10 mg cause significant 
reduction in trabecular & 
cortical bone mass in pts with 
RA.
Laan 1993 
Annals RD 1993; 
52:21-26










Cross sectional Z scores:
Female L.S: +0.33 
Female FN: -0.27 
Male LS: -0.67 
Male FN: -0.33
Disease duration, disease 
activity (ESR) & functional 
impaitment (HAQ score), 
independently of each other, 
contribute to the bone loss of 









99 49 Not Available 28:71 Mean: 1 HAQ 





40 27 Pre: 36.5 62 
Post: 65
16:24 Median: 2 0.62
Peel 1994 
A & R  1994 
37:983-991






Also Earty RA: 
16 4




20 received CS 
7.5 mg 20 weeks
85 on < 1 mg/day 
7 on 1 - 5mg/day 
10 on > 5mg/day
None
All received CS 
19 on 2.5 mg/day 
50 on 5mg/day 








On steroids (20 weeks): 
lose 8% trabecular BMD 
2% cortical BMD 
Off steroids (14 weeks):
Gain back 5% trabecular BMD 
1% cortical BMD 







No difference in spinal/hip 
BMD between patients and 
controls at entry, but over 1 
year patients lost 1% in L 
spine, 2% in F neck. Early RA 
(females only) lost 2.5% in L 




Longitudinal No difference in LS & FN BMD 
between patients and controls. 
Patients with disease duration 
<6/12 lost 3.9% FN BMD 







Cross-sectional % Decrease in BMD in patients 
as compared to controls 
Hand: 22.7 
Lumbar Spine: 10.7 
Femoral Neck: 16.3 
Total Body: 11.3
Low dose corticosteroids lead 
to reversible bone loss in 
patients, mainly in the 
trabecular bone.
Over 1 year the early RA pts 
lost higher bone mass both in 
LS & FN than pts with longer 
duration of RA. Steroid dose 
of 1 - 5 mg/day caused 
significantly loss of BMD in 
spine/FN. The loss of bone 
mass correlated with active 
disease (high CRP) and with 
worse disability (high HAQ).
Only patients with disease 
duration <6 months lost 
significant hip BMD. Hip BMD 
changes correlated with 
disease duration & spinal 
BMD changes correlated with 
initial Stoke index.
Hand BMD measurement 
with DXA correlated with 
BMD at other sites. In early 
RA patients, hand BMD 
correlated with grip strength 
and inversely with ESR.
Table 3:
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Not Available S. Osteocalcin RIA Cross sectional Marginally reduced OC levels in 
patients, but not statistically 
significant.
No difference in serum 
osteocalcin levels in early 
RA & controls.
Weisman 1986 
Arch Int Med 
1986;
146:701-704
38 43 55 Not Available 14 Not
Available
38 on oral CS 
6 mg not given
S. Osteocalcin RIA 
Aik P04 (Total)
Cross sectional 40% & 62% reduction in OC 
values in male & female patients 
respectively. Total Aik PO4 levels 
in female pts were higher than 
controls.
Patients with RA had 
lower levels of serum 
osteocalcin than controls. 
However, on stratification, 
only those on steroids 
had significantly lower 
levels than controls. 
Steroid non-users had 
similar levels to the 
controls.
Ekenstam 1986 
Annals RD 1986; 
45:485-490





20 mg for 1 week
S. Osteocalcin RIA Cross sectional Reduction of 54% in females & 
22% in male patients in OC values 
as compared to controls. 1 week 
of oral CS further reduced OC 
levels significantly.
Reduced levels of osteo­
calcin in inflammatory 
arthritis suggest reduced 
bone turnover. Oral CS 
suppresses bone turnover 
further.
Verstraeten 1986 
Annals RD 1986; 
45:852-857
64 59.2 All post­
menopausal
11.8 Most in 
Class lll/IV
28 on oral CS 
9 mg 4.7 years
Aik PO4 (Total) Cross sectional 
Controlled
Marginally raised total Aik 
Phosphatase in patients with RA. 
No effect of oral CS on the Aik 
P 04 levels.
This study mainly looks at 
the changes in LS & distal 
radius bone mass. The 
biochemical data is 


















Not Available Urinary pyridinoline 
(PYD) by ELISA (Urine 




422% increase in excretion of 
PYD in patients with RA, & 104% 
increase in patients with OA.
Patients with RA & OA 
excrete larger amounts of 
PYD than controls. In 
this study the urine was 
not collected in any 
uniform way & no 
information is given 





36 5 61 Not Available 10 I 6
II 13
III 20
9 on oral CS 
4.8 mg 3 years
Urinary Pyridinoline 
(PYD or HLP) & 
deoxypyridinoline 
(DPD or LP) by HPLC.
Cross sectional 
Controlled
200% increase in PYD & 205% 
increase in DPD in patients with 
RA. Active RA had 100% higher 
PYD levels than inactive RA.
Both PYD & DPD 
excretion in urine is 
significantly raised in RA, 
but PYD excretion, which 
is a marker of cartilage & 
bone degradation, corre­





42 52 Not Available <5 years : 
21
>5 years : 
21
1 - II 20 
III - V 22
None S. Osteocalcin RIA Cross sectional 
Controlled
Patients with active RA had 82% 
higher OC than controls & patients 
with inactive RA. (Activity defined 
by ARA criteria.)
OC levels depend on 
activity of RA. Those 
with high activity had 
higher OC levels. Aik 
P04 correlated with OC 













None Urinary Pyridinoline 
(PYD or HLP) & 
deoxypyridinoline 
(PDP or LP) by HPLC.
Cross sectional 
Case control
311% increase in PYD & 38% (not 
significant) increase in DPD in 
patients with RA. PYD levels 
correlated with CRP, ESR and 
negatively with grip strength.
PYD excretion in urine is 
significantly raised in 
patients with RA & it 
correlates with disease 







21 8 53 Not Available 8 II 22
III 7
None during the study, 
though 20 had received CS 
in varying doses in the past.
S. Osteocalin RIA Cross Sectional 
Controlled
No significant difference between 
patients & controls, those who 
took CS & those who did not.
Normal osteocalcin 
levels in patients with RA 
suggest normal rate of 
bone formation! Osteo­
penia in RA therefore 
could be secondary to 
increased bone resorp­
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Details not available but 
34 pts received <10 
mgs/day






(PYD or HLP) & 
deoxypyridinoline 
(DPD or LP) by 
HPLC, and spine & 






No difference in OC values in 
controls & patients, either early or 
advanced RA. However, OC levels 
were 58.5% higher in patients with 
late onset (>65 years) RA, but 
reduced over 1 year.
66% increase in PYD & 88% 
increase in DPD in patients when 
compared to controls. Patients 
with active RA (CRP >20) lost 2% 
& 3.5% BMD in spine & hip when 
compared to 1 % gain in both sites 
in patients with inactive disease 
(CRP <20).
Patients with late onset 
RA had more active
disease (TT ESR) & high 
levels of OC. Over one 
year the ESR & OC both 
dropped. OC therefore
depends on disease
activity & not on the onset. 
OC correlates with ESR 
(r=0.64, p=0.007) but not 
with Aik P04.
All patients with RA have 
higher levels of PYD & 
DPD in the urine. 
Patients with active RA 
lose more bone mass in 
the spine & hip, and have 
higher PYD excretion. 
The loss at femoral neck 
correlates with PYD 
excretion.
DEVELOPMENT AND VALIDATION OF THE METHOD OF MEASURING HAND BONE 
MINERAL CONTENT BY DUAL ENERGY X-RAY ABSORPTIOMETRY
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INTRODUCTION
This chapter describes the development of the technique to measure hand bone mineral 
content by dual energy x-ray absorptiometry (Hologic QDR 1000 machine). This 
machine is optimally designed to measure the BMC in hip and spine with an accuracy of 
2%. However measurement of BMC by the standard Hologic lumbar spine programme is 
both dependent on the soft tissue thickness and is non-linear for variations in BMC at the 
lower range as found in the hand.
To overcome this problem, Pye and Law (1990) described a method of scanning the 
hand on a built up plate made of perspex-aluminium to shift the overall hand BMC and 
the soft tissue found around the hand, towards the range observed in scanning the 
lumbar spine of normal subjects. The plate "hardens" the X-ray beam by removing the 
lower energy X-rays at the time of scanning.
We decided to use such a plate for our initial experiments in one of the three protocols 
we developed to measure hand BMC using Hologic QDR 1000 machine. We have 
compared the reproducibility and accuracy of these three methods using two human 
hand specimen. In this chapter we also describe more fully the method applied during 
the rest of the studies.
AIMS
The aim of this study was to develop a method of measuring hand bone mineral content 
(BMC) that could be applicable to patients with rheumatoid arthritis. This method needs 
to be objective, reproducible and accurate and considering the progressive nature of RA, 
quick and comfortable to the patient. It should also be not affected by hand deformities.
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MATERIALS AND METHODS
Development Of The New Method
Bone mineral content of the hand was measured by DXA using a Hologic QDR 1000 
machine. To determine the optimum hardening of the x-ray beam, successive layers of 
aluminium were added on a 2 centimeter perspex plate until the values of the Hologic 
parameters k, which is a function of the tissue attenuation characteristics of the beam, 
and d-theta which is used to convert beam attenuation reading to BMC values, matched 
those obtained by scanning the Hologic spine phantom. The plate was made large 
enough to fill the entire hand area.
The bone to soft tissue threshold, which differentiates bone from the soft tissue when 
analyzing, was altered to threshold 8, 8, 8 after testing several values on a number of 
hand scans. This threshold gave the best compromise between a reasonable definition 
of the bone outline without losing the small bones in the terminal phalanges. The bone 
edge detection between the metacarpals needed operator intervention to paint out the 
first interosseous muscle, whose comparative bulk can contribute up to 5% of the 
apparent bone mass. The other interosseii were left untouched to minimize the operator 
induced variability.
Evaluation Of Linearity
The use of the aluminium-perspex plate had no effect on the non-linearity of the Hologic 
spine analysis programme for variations in BMC at lower range. To achieve linearity, an 
aluminium step wedge resembling bone thickness’ of the hand was prepared to simulate 
hand and was scanned on this plate. Proportionality between the derived BMC result 
and the varying thickness’ of this plate was achieved by changing the Hologic linearity 
coefficients Q1, Q2 and Q3.




We selected 9 healthy normal volunteers (3 males, 6 females, age 26-53) to participate 
in the initial studies on measurement of hand bone mineral content by DXA. All these 
volunteers were hospital employees and did not suffer from any condition affecting hand 
bones. They had never used oral corticosteroids and none of the female volunteers 
were pregnant. All study subjects gave informed consent and the study was approved 
by the Ethical Committee of the Royal Cornwall Hospital, Truro.
Evaluation Of Reproducibility
The reproducibility of the method was determined by scanning 10 hands of normal 
volunteers. Each hand was positioned palm down on the plate with fingers extended, 
and scanned 5 times with repositioning between measurements.
Effect Of Hand Position
Five normal volunteers had their hands scanned in two different attitudes, flat on the 
plate and with slightly flexed fingers simulating a rheumatoid hand, to assess the effect 
of position on the measurement of hand BMC and hand bone mineral density (BMD) 
(Figures 1 and 2). In two volunteers, larger changes in hand positioning were studied by 
scanning one hand flat on the plate and also after making a tight fist.
Evaluation Of Inter-Observer Variability
The inter-observer variability of the hand BMC analysis was assessed by two observers 
analyzing three hand scans each five times.
Evaluation Of Alternative Protocols For Measuring Hand BMC And Assessment Of 
Accuracy
The accuracy experiments were conducted on two pathology hand specimens, one 
‘normal' and one ‘osteoporotic’, acquired from the Pathology Department of the Royal 
Cornwall Hospital, Truro.
The first 'normal' hand was from a 56 year old male patient with epilepsy who underwent 
an amputation for acute pressure gangrene of the left upper limb. He did not suffer from
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arthritis and did not have any long-term illness affecting the left hand. The x-ray of the 
amputated hand revealed bones with no radiographic evidence of osteoporosis.
The second ‘osteoporotic1 hand specimen was from a 62 year old patient with malignant 
mesothelioma. The intractable pain and swelling in the left upper limb led to the 
palliative amputation of his left upper limb. He had not used his left upper limb for over 
six months and the x-ray of this hand before amputation revealed osteopenic bones. 
After amputation, both patients gave consent for their hands to be used for research 
purposes.
Each hand was scanned twenty times each using following three protocols:
Protocol 1: Hand positioned on the custom-built plate, image acquired by Hologic lumbar 
spine software and analyzed using the method described above.
Protocol 2: Hand positioned on scan table without using the plate, image acquired by 
Hologic lumbar spine software and analyzed by Hologic forearm software.
Protocol 3: Hand positioned on scan table without using the plate, image acquired and 
analyzed by Hologic forearm software.
To determine the accuracy of each method, the results of the observed hand BMC were 
compared with the ashed weight of hand bones.
Ashing Protocol
Each hand was dissected and individual bones were separated from the soft tissue. The 
bones were 'fixed' in formalin overnight before drying in a small oven for two hours at
80° C. They were then sawn into small sections, each approximately 1cm^ to fit in the 
crucibles used for ashing. A set of clean, dry crucibles was weighed and the bone 
sections distributed amongst them so that there were approximately two sections per
crucible. These were then baked at 700° C for two hours and allowed to cool. A 
solution of 4M nitric acid was pipetted over each sample and the crucibles were returned
to the oven and the temperature slowly increased to 700° C. The crucibles were then 
baked for a further one hour. After incineration was complete, the crucibles were 




Development Of The Perspex-Aluminium Plate And Linearity
For our scanner, a plate thickness of 7 mm aluminium plus 20 mm perspex was found to 
give closest match to the value of k and d-theta used in the Hologic spinal analysis 
programme. We therefore prepared a custom-built plate of this thickness for further use 
in hand BMC measurements. To obtain linearity between the results of BMC of small 
thickness hand bones, Hologic linearity coefficients were altered to Q1 =0.203, 0.226, 
Q2=0.405, 0.427 and Q3=0.608, 0.616, which were used in all further analysis.
Experiments On Volunteers: Reproducibility, Effect Of Hand Position And Inter- 
Observer Variability.
For the method of acquisition and analysis described by us, the coefficient of variation 
(CV) for hand BMC was 2.3% and for hand BMD 1.3% (Table 1).
Table 1: Hand Bone Mineral Content Reproducibility:
A B C D E F G H I J
BMC: 1 38.2 35.14 29.39 29.81 32.56 35.1 30.91 29.68 32.22 33.04
BMC: 2 37.44 35.74 29.41 30.68 33.1 35.5 30.28 30.01 32.46 33.3
BMC: 3 37.92 36.1 29.49 30.42 32.96 35.3 31.34 30.83 33.08 32.84
BMC: 4 38.54 36.2 30.23 31.4 33.4 36.4 31.3 30.43 33.1 33.38
BMC: 5 37.9 35.83 30.15 29.54 32.94 36.38 30.7 30.79 32.85 32.98
MEAN 38 35.8 29.73 30.37 32.99 35.73 30.9 30.34 32.74 33.1
STD 0.363 0.371 0.374 0.657 0.271 0.548 0.394 0.446 0.348 0.201
Note: Ten hands (A to J) were scanned five times each. STD = Standard Deviation.
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Changing the hand position from flat to slightly flexed (simulating a rheumatoid hand) or 
tight fist did not alter the precision of the BMC result, though it did alter the BMD, which is 
area dependent. The hand BMD increased by 13.1% (Figures 1 and 2) with the hand in 
a slightly flexed position and by 30.8% in a tight fist position (Table 2). The first inter­
osseous muscle could not be painted out with the hand in a tight fist position. Despite 
this, the hand BMC did not change with the hand in flat or a fist position (Figures 3 & 4).
Table 2: Effect of hand position on hand BMC: Five hands scanned flat and semiflexed.
POSITION FLAT SEMI-FLEXED
BMC BMD BMC BMD
HAND 1 35.14 0.387 35.88 0.426
HAND 2 31.07 0.344 31.82 0.456
HAND 3 46.70 0.403 46.17 0.454
HAND 4 31.22 0.321 31.81 0.432
HAND 5 37.49 0.375 37.68 0.428
Analysis by a second observer did not change the precision of BMC or BMD result (see 
Table 3).
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Table 3: Inter-Observer Variability
OBSERVER:! MEAN
Scan 1 37.44 37.42 37.48 37.42 37.4 37.43
Scan 2 29.16 29.15 29.22 29.17 29.14 29.16
Scan 3 43.28 43.29 43.26 43.23 43.29 43.27
uu>
STD OBSERVER: 2 MEAN STD
.027 37.39 37.43 37.44 37.42 37.45 37.42 .02
.025 29.21 29.2 29.16 29.18 29.16 29.18 .02
.011 43.22 43.24 43.20 43.26 43.30 43.24 .02
Evaluation Of Alternative Protocols For Measuring Hand BMC And Assessment Of 
Accuracy
For each of the three protocols, the observed hand BMC, coefficient of variation and 
scanning times as well as the final ashed weights of both hands are shown in Table 4.
Table 4: Three Protocols Of Hand BMC Measurement
Protocol 1 Protocol 2 Protocol 3 Ash Weight
BMC CV BMC CV BMC CV
Normal Hand 35.47 1.18 24.76 0.97 26.48 2.91 27.48
Osteoporotic Hand 32.43 1.11 14.54 4.26 19.38 3.3 23.6
Ratio: 1.09 1.70 1.36 1.16
Normal/Osteopenic
Scan Time 10 Minutes 10 Minutes 20 Minutes
Analysis Time 5 Minutes 8 Minutes 8 Minutes
Note: The BMC and ash weights are in grams.
Protocol 3 was the slowest, requiring twice the scanning time as compared to protocols 1 
and 2. For the first hand, protocols 2 and 3 were more accurate with better 
reproducibility than protocol 1, but with the osteoporotic hand, protocols 2 and 3 failed to 
delineate the bones properly and lost the advantage of superior accuracy. This is 
reflected in the ratio of normal to osteoporotic hand BMC. Protocol 1 effectively 
delineated normal as well as osteoporotic bones and thus the ratio of normal to 
osteopenic hand BMC by protocol 1 was the closest to that by ashing. It however over­
estimated the amount of hand BMC by an average multiplicative factor of 1.3.
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COMMENTS AND CONCLUSIONS
1. We have developed a novel method of scanning and analyzing hand BMC using dual 
energy x-ray absorptiometry by altering an existent spine protocol.
2. Our method is reproducible and accurate for both, normal and osteoporotic hands.
3. In normal volunteers, the reproducibility of our method did not depend on the 
observer.
4. Change in hand position from flat to semi-flexed (simulating a rheumatoid hand) did 
not change the BMC significantly, but increased the BMD which is dependent on the 
surface area. For long term studies therefore hand BMC, which is area independent, 
is a preferred measurement.
5. The other two methods, using existent forearm protocols, are either less accurate 
than our method when dealing with an osteoporotic hand, or require much longer 
scanning time. This may prove problematic in dealing with patients with painful 
arthritis affecting hands.
6. We therefore used Protocol 1 for the measurement of hand bone density in further 
experiments described in this thesis.
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Figure 1: Hand scan of a normal volunteer using perspex-aluminium plate. Hand position: flat.
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Figure 2: The same hand scanned in a semi-flexed position. Note the effect on hand BMC and hand BMD.
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Figure 3: Hand position: flat.
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MEASUREMENT OF HAND BONE MINERAL CONTENT BY DUAL ENERGY X-RAY 
ABSORPTIOMETRY IN NORMAL VOLUNTEERS
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INTRODUCTION
Measurement of hand bone mineral content (BMC) by dual energy x-ray absorptiometry 
(DXA) is an accurate and reproducible technique as shown in the last chapter. It does 
not depend on the hand position or on the operator. This chapter describes the 
application of this technique to normal volunteers to estimate the normal ranges of hand 
BMC in males and females and also to assess the effect of sex, body size and hand 
dominance on hand BMC in healthy individuals.
SUBJECTS AND METHODS
Ninety five normal volunteers (46 males, age 24 to 81, median 33 and 49 females, age 
20 to 83, median 41, 31 pre- and 18 postmenopausal) were enrolled from the hospital 
staff, spouses and voluntary workers in the Royal Cornwall Hospital, Truro. Written 
informed consent was obtained. There were no major differences in the use of the hand 
and none of them were manual labourers. Those suffering with any disease affecting 
the hands, those who had used steroids any time in their life and in case of women, 
those who were pregnant or were likely to be pregnant were excluded.
Variables recorded for the healthy volunteers were age, weight, height, forearm span 
(length of forearm from the ulnar styloid to the olecrenon process measured by a 
specially made measuring bench on which the forearm was positioned), hand volume 
(measured as water displaced by hand distal to the ulnar styloid process, the 
reproducibility of this method was CV = 1.8%), hand dominance and the position of the 
hand while scanning. The physical characteristics of the volunteers are shown in Table
1. All volunteers underwent hand BMC measurements on both hands by DXA.
Thirty seven out of ninety five volunteers (9 males and 28 females, 14 pre and 14 
postmenopausal) agreed to be re-scanned and underwent a repeat measurement of 
hand BMC after 1 to 4 years to establish the annual rate of change in hand BMC in 
healthy controls.
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Table 1: Physical characteristics of normal volunteers. Median (IQR).
Male Female
n=46 n=49
Age in years 42 (17) 43.7 (18.3)
Age range 24-81 20-83
Premenopausal - 23
Weight in kg 75.4 (9.7) 63.8 (10)
Height in cm 175.4 (6) 161.1 (6.8)
Dominant hand volume in cc 345 (181) 313(43.1)
Forearm span in cm 27 (4.2) 24.3(1.6)
ANALYSIS
The statistical analysis was carried out using the NCSS statistical package. For 
comparisons within the group, paired t-test and Wilcoxon matched pair signed ranks test 
were used depending upon the distribution of the variables. Intergroup comparisons 
were performed by Mann-Whitney U test or unpaired T-test according to distribution of 
variables. Spearman's correlations were calculated. Partial correlations were calculated 
to allow for the effects of covariates such as age, height and weight. Differences 
between groups were corrected for other covariates by using multiple regression.
RESULTS
Hand BMC at Baseline
The hand bone mineral content in male and female volunteers at baseline is shown in 
Figure 1 and Table 2.
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Table 2: Dominant and non-dominant hand BMC in normal volunteers.
Dominant Hand Non-Dominant Hand
Median IQR Range Median IQR Range
Male 46.71 7.48 32.56, 62.98 45.7 7.47 31.59, 61.63
Female 31.35 6.17 19.11,39.79 31.2 5.85 19.28, 37.66
In males the mean total hand BMC (dominant plus non-dominant) was 90.9 gms (95% Cl 
86.9 - 95, SD 13.7). In females the mean total hand BMC was 62.2 gms (95% Cl 59.8 - 
64.5, SD 8.3).
Effect Of Body Size On Hand BMC
The effect of the covariates age, height, weight, forearm span and hand volume on the 
hand BMC was examined by Spearman's correlation. In males, the total hand BMC 
correlated with forearm span (r=0.5, p=0.0006), height (r=0.57, p<0.0001), weight 
(r=0.58, p<0.0001) and hand volume (r=0.66, p<0.0001). In females the total hand BMC 
correlated with forearm span (r=0.3, p=0.03), weight (r=0.4, p=0.003), hand volume 
(r=0.49, p=0.0008) and height (r=0.66, p<0.0001). No significant correlation was found 
between hand BMC and age in males and females (Figure 2).
Effect Of Hand Dominance On Hand BMC
The hand volume was significantly greater in dominant than non-dominant hands of 
males (p = 0.0001) and females (p = 0.005), assessed by Wilcoxon matched pairs 
signed ranks test. In spite of this difference in the hand volumes, there was no statistical 
difference between the BMC of the dominant and non-dominant hands in male and 
female volunteers as shown by paired t-test.
Comparison Of Hand BMC In Male And Female Volunteers
After correcting for height, weight, volume and forearm span, male volunteers had 
significantly more bone mass than female volunteers ( Figure 1, p= 0.01).
63
Hand BMC At 12 Months
The comparison of the hand BMC results at baseline and at 12 months are shown in 
Table 3. Over 12 months, both male and female normal controls did not have any 
significant change in their hand BMC. When the female control population was divided 
according to their menopausal status, the postmenopausal group was found to lose 
significant amount of hand BMC over one year (p=0.001).




Males 9 0.9 1.73 0.2
Females (Pre-M) 14 -0.17 3.5 0.6
Females (Post-M) 14 -1.6 3.11 0.001
Females (all) 28 -0.9 1.92 0.08
COMMENTS AND CONCLUSIONS
1. In normal volunteers, the hand BMC was dependent on the body size and correlated 
with hand volume, weight and height.
2. Unlike the BMC in spine and hip, there was no significant correlation between hand 
BMC and age in volunteers.
3. In the population studied, there was no significant difference between the hand BMC 
of the dominant and non-dominant hand either in males or in females
4. After correcting for body size, males had higher hand BMC than females.
5. On annual follow-up, male and pre-menopausal female volunteers did not lose any 
hand BMC, but post-menopausal females did lose significant amount of hand BMC
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List of Figures
Figure 1: Dominant hand BMC in grams in normal volunteers. After correcting for body 
size, male volunteers had significantly higher BMC than female volunteers (p=0.01).
Figure 2: Hand BMC plotted against age in male and female volunteers.
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MEASUREMENT OF HAND BONE MINERAL CONTENT BY DUAL ENERGY X-RAY 
ABSORPTIOMETRY IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS: A 
CROSS-SECTIONAL AND ONE YEAR LONGITUDINAL STUDY
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INTRODUCTION:
Periarticular as well as generalized osteoporosis are some of the commonest 
extraarticular manifestations of rheumatoid arthritis (Woolf 1991). Many studies have 
looked at generalized osteoporosis in patients with RA by measuring the bone mineral 
density in spine and hip; and measurement of BMD at distal radius has been used to 
assess the periarticular osteoporosis (for details, see Table 2, Chapter 2). Our technique 
of hand bone densitometry may provide a new tool to study both, generalized and 
periarticular osteoporosis in patients with RA. We have therefore applied it to a cohort of 
patients with RA in a cross-sectional study and then in a one year longitudinal study to 
see whether bone density is reduced in rheumatoid arthritis, whether there is an ongoing 
loss and whether the bone density or the bone loss correlate with other measures of 
disease activity and outcome.
SUBJECTS AND METHODS: THE CROSS-SECTIONAL STUDY
Fifty-six patients (22 males and 34 females) with rheumatoid arthritis of differing severity 
and with duration greater than two years had both hands scanned to determine BMC. 
These patients were chosen at random from out-patients and in-patients of the Duke of 
Cornwall Rheumatology Unit, Truro. The clinical activity was assessed by Ritchie Index 
(Ritchie et al 1968) and a swollen joint score (number of joints with tenderness and 
synovitis), the functional status by Health Assessment Questionnaire (HAQ) expressed 
as functional disability index (Fries et al 1980) and radiological severity was determined 
on hand X-rays by Larsen's grades (Larsen et al 1977) and Modified Sharp's method 
(Sharp et al 1985). The disease activity was measured by plasma viscosity and C- 
reactive protein. All patients underwent BMC measurement of both hands (Figure 1).
SUBJECTS AND METHODS: THE ONE YEAR LONGITUDINAL STUDY
Out of the original fifty-six patients, thirty-nine (16 males aged 30-84, median 65.5 years, 
and 23 females aged 33-84, median 63 years, 7 pre-menopausal) attended follow up 
one year later. They underwent a full assessment as explained above including a repeat 
hand BMC measurement.
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All except three patients were on DMARDs during the study period (13 penicillamine, 9 
sulfasalazine, 4 sodium aurothiomalate intra-muscular, 4 methotrexate, 4 azathioprine, 1 
hydroxychloroquine and 1 patient received sodium aurothiomalate injection and 
sulfasalazine together). During the study period none of the patients received oral 
corticosteroids though eleven patients had used oral steroids in the past for other 
reasons.
The hand BMC data on the normal volunteers (control population) described in the last 
chapter was used for comparison with the patients.
ANALYSIS
Number Cruncher Statistical System (NCSS) statistical programme was used for 
statistical analysis. Hand BMC of controls and patients was compared by Mann-Whitney 
test. Baseline results in patients were compared with their results at month 12 by 
Wilcoxon matched pairs test. The differences in hand BMC (Initial - Final) were 
correlated with the baseline parameters of disease activity by Spearman's correlation. 
Comparisons between controls and patients with RA in pairs were made by carrying out 
an analysis of covariance with age, weight and height as covariates. Only those 
covariates which indicated a significant association with BMC were included in the final 
analysis.
RESULTS
Results At Baseline: The cross-sectional study.
Demographic characteristics of patients with rheumatoid arthritis are described in Table 1 
and the disease characteristics of patients at the start of the study are shown in Table 2.
The corrected mean dominant hand BMC in male patients was 7.5% reduced (p=0.003) 
when compared to male controls and in female patients the corrected mean dominant 
hand BMC was 7.8% reduced (p=0.01) when compared to female controls (Table 3). 
There was no statistical difference between the dominant and non-dominant hand BMC 
in male and female patients with RA by the paired t-test. The hand BMC inversely 
correlated with age in female (r=-0.44, p=0.01) but not in male patients.
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Table 1: Demographic Characteristics Of The Patients:
Male (n=22) Female (n=34)
Median Age (Range) 64 (29-83) 64 (25-86)
Premenopausal -  5
Median Disease Duration 7 years 10 years
Disease Duration Range 2-25 years 2-40 years
Number on DMARDs 16 26
Past Corticosteroid Use 4 7
Table 2: Disease Characteristics Of The Patients (n=56): The Cross-sectional Study
Median IQR
Early Morning Stiffness 30 77
Ritchie Articular Index 10 14
Number of Swollen Joints 3 4
HAQ Score 1.35 1.05
C Reactive Protein 14.7 46
Plasma Viscosity 1.8 0.29
Larsen Score 20.5 27
Table 3: Hand bone mineral content in patients: The Cross-sectional Study
Control Patients
Median 95% Cl Median 95% Cl 
Male 46.53 44.7-47.9 42.70 41-44.4
Female 30.82 29.6-32 28.4 27.2-29.5
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The Mann Whitney test was used to compare age, height and weight in volunteers and 
patients since the groups were not matched for these covariates. Age was significantly 
higher in patients when compared with volunteers (males p=0.0001, females p<0.0001), 
height was lower in male patients than male volunteers (p=0.01) but weight was not 
significantly different in either sexes in these two groups. The total hand BMC (Dominant 
and Non-dominant) in patients was therefore corrected for height and age in male 
patients and for age in female patients by using multiple regression with group and the 
covariates as independent variables. Male patients (corrected for age and height) had 
lower hand BMC than male volunteers (p=0.005) and female patients (corrected for age) 
had significantly lower hand BMC than female volunteers (p<0.005).
7 female and 4 male patients had used oral corticosteroids at some stage of their 
disease but there were no statistically significant differences in hand BMC between users 
and non-users of either sex using Mann Whitney test. To allow for the confounding effect 
of other variables, partial correlations (Spearmans) of patients total hand BMC were used 
eliminating the effect of age, height and weight. The hand BMC showed inverse 
correlation with disease duration (r=-0.62, p=0.0003), Larsen score (r=-0.62, p=0.0002) 
and Sharp's score (r=-0.69, p<0.0001) in females. In male patients the hand BMC also 
showed an inverse but much weaker and not significant correlation with disease duration 
(r=-0.23, p=ns), Larsen score (r=-0.24, p=ns) and Sharp's score (r=-0.31, p=ns). Figure 
2 shows the correlations between hand BMC (all patients, male and female) with HAQ 
score, disease duration, Sharp’s score and Larsen score. Ritchie index, swollen joint 
score, EMS or HAQ did not show any significant correlation with the hand BMC.
A comparison of hand BMC values in normal volunteers and patients with RA is shown in 
figure 3.
RESULTS AT 12 MONTHS: THE ONE YEAR LONGITUDINAL STUDY
Thirty-nine patients (16 males aged 30-84, median 65.5 years, and 23 females aged 33- 
84, median 63 years, 7 pre-menopausal) participated in the longitudinal study and 
attended follow up one year later. They underwent a full clinical and laboratory 
assessment including hand BMC measurement. Over the study period, there was no 
significant change in the measured parameters of disease activity (Table 3) although the 
Larsen score and the HAQ score worsened significantly.
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Table 3: Disease Characteristics Of The Patients (n=39) At Entry And At 1 Year: The
Longitudinal Study
Median (IQR) Entry 1 Year *p Value
EMS 30(90) 30(88) = 0.2
Ritchie 10(14) 10(13) = 0.6
Swollen Jts. 3(3) 3(6) = 0.5
HAQ Score 1.5(1.3) 1.6(1.3) = 0.01
CRP 14(43) 14(44) = 0.2
P. Viscosity 1.78(.26) 1.66(.16) = 0.1
Larsen Score 25(30) 29(37) = 0.001
Hand BMC (Grams) 30(16) 31(15) = 0.17
Note: *Wilcoxon matched pairs test. IQR = Inter quartile range, Ritchie = Ritchie articular 
index, the Larsen's score was derived from both hand x-rays.
There was a trend showing loss of hand BMC over one year in males but these changes 
did not reach statistical significance (Median loss 0.94 grams, 2.24%, 95% Cl for percent 
loss -0.86 to 4.14, p=0.1) and there was no significant change in females (0.03 grams,
0.11%, 95% Cl for percent loss -4.52 to 5.14, p=0.2, Table 4, Figure 2).
Table 4: Percent Change In Dominant Hand BMC In Patients With RA Over One Year
n= Median IQR *p=
Males 16 -2.24 4.33 0.1
Females 23 0.11 11.56 0.2
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Note: *p value refers to the paired differences between hand BMC at entry and at one 
year by Wilcoxon Matched Pairs Test.
The individual rate of change however varied between 8% gain to 33% loss with greatest 
losses in certain postmenopausal women (Figure 4). There was no correlation between 
change in hand BMC with parameters of disease activity.
Numbers were too small to examine the effect of past use of corticosteroids on hand 
BMC.
Effect Of Menopause On Hand BMC
To investigate whether menopausal status affected the hand BMC at the baseline and 
its rate of loss over one year, analysis of covariance (ANCOVA) was used with presence 
of rheumatoid arthritis and menopause as two separate risk factors after correcting for 
confounders like age, height and weight. At baseline, both the presence of the disease 
(p<0.0001) and menopausal status (p=0.007) were important determinants of hand BMC 
however, for the rate of loss of hand BMC, menopausal status (p=0.01) and not 
presence of the disease (p=0.8) was the main determinant. In summary therefore, the 
changes in hand BMC in postmenopausal female patients are not solely disease 
dependent.
CONCLUSIONS AND COMMENTS
1. Patients with rheumatoid arthritis had reduced hand bone mass than sex matched 
volunteers after correcting for age and body size.
2. Female patients had reduced hand bone mass than male patients after correcting for 
body size, age and disease duration.
3. There was no significant difference between the bone mass in the non-dominant and 
dominant hands in male or female patients.
4. Hand BMC inversely correlated with age in female patients only.
5. Hand BMC correlated inversely with disease duration, Larsen’s and modified Sharp’s 
scores in both, male and female patients.
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6. The hand BMC in female patients with established RA is dependent on both, the 
menopausal state as well as the presence of the disease.
7. Over one year study period, there was no significant change in most of the 
parameters of disease activity except HAQ score and Larsen’s score which worsened 
significantly.
8. Over one year period there was a wide variation in individual rate of change in hand 
BMC in patients although as a group, in patients with disease duration of more than 
two years, there was no change in hand BMC.
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Figure 1: Hand BMC in a patient with rheumatoid arthritis.
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TWO YEAR FOLLOW-UP STUDY OF HAND BONE DENSITOMETRY AND BONE 
BIOCHEMISTRY IN EARLY RHEUMATOID ARTHRITIS
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INTRODUCTION
In the last chapter, we have shown that patients with rheumatoid arthritis had reduced 
hand bone mass as compared to normal volunteers. However over one year period, we 
could not find any significant change in the hand BMC in this group of patients with 
established RA. One of the reasons for this lack of change in hand BMC could be the 
fact that most of these patients had a relatively long disease duration. Disease duration 
is an important factor to be considered when studying the effect of RA on bone mass. 
We therefore at the same time as performing the cross-sectional and longitudinal studies 
on patients with established RA, initiated an “Early RA Clinic” to study changes in hand 
BMC in patients with recent onset rheumatoid arthritis. Subsequently two other studies 
on axial skeleton in patients with RA (Gough et al 1994b, Shenstone et al 1994) have 
shown that the deleterious effect of RA occurs mainly in the first year of the disease and 
there were significant differences in the rate of loss of bone between patients with 
diseases duration of less than 1 year and those with disease duration of more than 1 
year.
In this chapter, we describe a two year prospective study of changes in hand BMC in 
patients with early rheumatoid arthritis (disease duration less than two years). We have 
also studied the biochemical markers of bone metabolism over this period to assess 
mechanisms of and response to bone loss in rheumatoid arthritis.
SUBJECTS AND METHODS
Forty three patient (17 males aged 35-77, median 53 years, and 26 females aged 29-71, 
median 55 years, 8 pre-menopausal) with early RA (disease duration median 9 months, 
IQR 10, range 2 to 22 months, diagnosed by ARA Criteria 1987), were selected 
consecutively from the out-patients and in-patients of the Duke of Cornwall 
Rheumatology Unit, Truro. None of these patients were taking any disease modifying 
anti-rheumatic drugs (DMARDs) at entry to the study, but during the study period, all 
except one were started on DMARDs (20 sulfasalazine, 8 penicillamine, 5 
hydroxychloroquine, 3 sodium aurothiomalate intra-muscular, 3 pyritinol, 1 methotrexate 
and 1 patient received sodium aurothiomalate injection and sulfasalazine together). 
Patients with any other diseases likely to affect bone metabolism and female patients 
likely to be pregnant during the study period were excluded from the study. During the 
study period none of the patients received oral corticosteroids though three patients had
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used oral corticosteroids in the past (at least 12 months before entry into the study) for 
other reasons. Informed written consent was obtained at the baseline visit.
The hand BMC data on the normal volunteers (control population) described in Chapter 
Four and in patients with longer duration of RA (“Late RA Group”) described in Chapter 
five was used for comparison with these patients with shorter duration of RA (the “Early 
RA Group”).
Clinical Assessment and Bone Density Measurement:
All patients were assessed at baseline and then at six monthly interval over the next two 
years. All 43 patients had at least three assessments (baseline, six months and one 
year). 39 patients had four assessments (up to month eighteen) and 29 patients 
completed five assessments (two years). At each visit a physical examination was 
performed. The clinical activity was determined by early morning stiffness (EMS), Ritchie 
articular index (Ritchie et al 1968) and swollen joint count. The general functional status 
was estimated by Health Assessment Questionnaire (HAQ) (Fries et al 1980) score, 
hand function was examined by grip strength and radiological severity was assessed on 
hand x-rays by Larsen score (Larsen et al 1977) by one observer. C reactive protein 
(CRP) and plasma viscosity was measured at each visit. BMC of the dominant hand 
was measured at each visit by DXA (Hologic QDR 1000) using a custom-built perspex- 
aluminium plate and locally modified spine analysis programme as described in the third 
chapter
Biochemical Markers of Bone Metabolism:
At each visit bone metabolism was assessed by urinary pyridinoline and deoxy- 
pyridinoline (reflecting osteoclastic activity (Eastell 1994)), serum osteocalcin and bone 
specific alkaline phosphatase (both reflecting osteoblastic activity (Eastell 1994)).
Urinary Collagen Cross-links Excretion
A two hour fasting urine collection was made by all patients at each assessment visit. 
The urinary excretion of pyridinoline and deoxy-pyridinoline is not affected by diet, 
though the same specimen of urine was also used for measurement of urinary calcium 
which can be diet dependent. The urine was collected in hospital in plain bottles, the
volume was recorded and two 2 ml aliquots were stored at -20°c for further analysis.
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The remaining urine was acidified with 10 ml of 10% HCI and was used for measurement 
of calcium creatinine ratio. The collagen crosslinks were measured using the method of 
Black et al (1988). One ml of urine was hydrolysed with one ml of concentrated HCI
(with final concentration of 6 M) for 16 hours at 116°C. The resulting hydrolysates were 
fractionated by cellulose CFI column chromatography. The crosslinks were separated 
and quantified by reverse phase HPLC with fluorescent spectroscopy using 
heptaflurobutyric acid as an ion pairing agent. For each specimen duplicate samples 
were analyzed and from these the urinary excretion rates of the pyridinium cross-links 
were expressed as nmol/mmol of urinary creatinine. To determine the normal ranges for 
our laboratory, early morning urine samples were also collected from 57 normal 
volunteers (13 males, 36 pre and 8 post menopausal females, age range 20 to 75) who 
were different from the volunteers who took part in the hand scan experiment. None of 
these volunteers suffered from any conditions that could affect the bone metabolism and 
none were taking corticosteroids. For our laboratory, the intra-assay variation was 10% 
for pyridinoline and 15% for deoxy-pyridinoline. A control sample with known quantities 
of pyridinoline and deoxy-pyridinoline was included in each run for quality control.
Serum Osteocalcin Measurement
Serum osteocalcin concentrations were determined using a commercially available 
radioimmunoassay (RIA) kit (CIS (UK) Ltd., High Wycombe, England). The test 
sensitivity has been determined to be 0.5 ngm/ml. The precision was assessed by using 
the control serum provided at regular intervals. For our laboratory the coefficient of 
variation (CV) of the method was found to be around 5%. Each determination was 
carried out in duplicate and samples giving higher CV were repeated for confirmation. 
The normal values (mean (SD)) for men were 6.5 (2.3), all women 4.8 (2.1) and for post­
menopausal women 7 (3.7).
Estimation Of Bone Isoenzyme Of Alkaline Phosphatase
The bone alkaline phosphatase activity was determined using the wheat germ lectin 
precipitation method described by Rosalki et al (1984) using a commercially available kit 
(Isoenzymes of alkaline phosphatase, Boehringer Mannheim UK). After the total activity 
of serum alkaline phosphatase was determined (using PNP AMP buffer, kit from Randox 
laboratories), bone alkaline phosphatase was precipitated using the lectin from wheat 
germ and the residual alkaline phosphatase activity was measured in the supernatant 
(Olympus AU 5000 machine). Taking the dilution factor into account, bone alkaline 
phosphatase activity was calculated as:
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Bone Aik Phos = 1.118 * Total Aik Phos - 2.35 * activity in supernatant. The normal 
values for our laboratory were total alkaline phosphatase upto 115 u/l and bone specific 
alkaline phosphatase upto 65 u/l.
ANALYSIS
Number Cruncher Statistical System (NCSS) statistical programme was used for 
statistical analysis. Hand BMC of controls and patients was compared by Mann-Whitney 
test. Comparisons between controls and patients were made by carrying out an analysis 
of covariance with age, weight and height as covariates. Only those covariates which 
indicated a significant association with BMC were included in the final analysis. Baseline 
results in patients were compared with their results at month 6, 12, 18 and 24 by 
Wilcoxon matched pairs test. The percent change in hand BMC was calculated by 
comparing the results at every assessment visit with the baseline results. The annual 
percent loss was correlated with the mean values of variables by Spearman's correlation.
RESULTS AT BASELINE
The demographic characteristics of the patients are shown in Table 1.
Table 1: Demographic Characteristics Of Patients (n=43) With Early RA
Male Female
17 25
Median Age 53 55
Age Range 35-77 29-71
Premenopausal 8
No. on DMARDS 16 25
Past steroid use 0 3
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Disease Activity At Baseline
Table 2 shows the various parameters of disease activity at baseline.
Table 2: Baseline Disease Characteristics In 43 Patients With Early RA: Median (IQR)
Early Morning Stiffness 45 (40)
Swollen Joints (Hands) 4 (7)
Tender Joints (Hands) 14 (23)
Ritchie Score 14 (16)
Grip Strength Dominant Hand 27.3 (19)
Larsen Score 4 (8)
No. Of Erosions On Hand X-Rays 1 (3)
C Reactive Protein 17 (58)
Plasma Viscosity 1.84 (0.22)
Hand Bone Mineral Content At Baseline
At the initial assessment, male and post-menopausal female patients had significantly 
lower hand BMC than controls after correcting for age, height and weight (Table 3, male 
patients 7% reduction, p=0.04, postmenopausal female patients 8.5% reduction, 
p=0.04). The premenopausal female patients had higher hand BMC than controls, but it 
was not statistically significant.
Table 3: Hand bone mineral content in patients and controls (in grams) at baseline
Control Patients
Median 95% Cl Median 95% Cl
Male 46.53 44.7-47.9 43.49 42.6-44.3
Pre-menopausal 31.57 30.2-35.1 34.0 28.9-40.5
Post-menopausal 30.12 29.3-30.9 27.76 26.9-28.5
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Biochemical Markers of Bone Metabolism At Baseline:
At baseline, serum osteocalcin was significantly higher in female (p=0.0004) but not in 
male patients as compared to normal controls. Urinary excretion of 
pyridinoline/creatinine (Pyd/Cr) and deoxy-pyridinoline/creatinine (Dpd/Cr) were 
significantly elevated in male and female patients as compared to controls at baseline 
(for males: Pyd/Cr p=0.005, Dpd/Cr p=0.01; for females: Pyd/Cr p=0.001, Dpd/Cr 
p=0.003). The serum levels of bone isoenzyme of alkaline phosphatase was in the 
normal limits, both in male and female patients.
RESULTS: TWO YEAR FOLLOW-UP
Disease Activity On Follow Up
Over the two year study duration, patients showed overall improvement in disease 
activity with fall in EMS, Ritchie articular index, swollen joint count, tender joint count, 
plasma viscosity, CRP and improvement in grip strength. The Larsen score and the 
number of erosions on hand x-rays progressively worsened over two year period. There 
was no significant change in the HAQ score (for detailed results see Table 4, Figure 2).
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Table 4: Percent Changes (From Baseline) In Disease Characteristics In Patients Over 
Two Years: Non-parametric Wilcoxon matched pairs test, median (IQR).
P a i r e d  D i f f e r e n c e s B a s e l i n e P e r c e n t P * P e r c e n t P * P * *
I n  V a r i a b l e s V a l u e C h a n g e  A t  
O n e  Y e a r
V a l u e C h a n g e  
A t  T w o  
Y e a r s
V a l u e V a l u e
E a r l y  M o r n i n g  
S t i f f n e s s
4 5  ( 4 0 ) - 3 3 . 3  ( 1 4 0 ) 0 . 0 4 - 7 7  ( 9 5 ) 0 . 0 1 0 . 1 8
S w o l l e n  J o i n t s  
( H a n d s )  ®
4 ( 7 ) - 6 6 . 6  ( 1 0 0 ) 0 . 0 0 1 - 5 0  ( 1 1 7 ) 0 . 0 0 3 0 . 5
T e n d e r  J o i n t s  
( H a n d s )  ®
1 4 ( 2 3 ) - 3 8  ( 1 0 3 ) 0 . 0 0 7 - 4 6  ( 7 8 ) 0 . 0 0 0 3 0 . 2
R i t c h i e  S c o r e 1 4 ( 1 6 ) - 2 8  ( 7 5 ) 0 . 0 1 - 3 9  ( 6 0 ) 0 . 0 0 0 2 0 . 1 6
G r i p  S t r e n g t h  
D o m i n a n t  H a n d
2 7 . 3  ( 1 9 ) 3 9  ( 1 0 4 ) 0 . 0 0 1 4 8  ( 8 8 ) 0 . 0 0 4 0 . 4
L a r s e n  S c o r e 4 ( 8 ) 6 4  ( 3 0 0 ) 0 . 0 0 0 0 1 0 0  ( 2 8 5 ) 0 . 0 0 0 1 0 . 0 4
N o .  O f  E r o s i o n s  
( X - R a y :  B o t h  H a n d s )
1 ( 3 ) 6 6 . 6  ( 2 1 3 ) 0 . 0 0 0 3 2 3 0  ( 3 5 8 ) 0 . 0 0 0 2 0 . 0 0 3
C  R e a c t i v e  P r o t e i n 1 7 ( 5 8 ) - 3 5  ( 9 1 ) 0 . 0 1 - 4 1  ( 1 8 9 ) 0 . 5 0 . 4
P l a s m a  V i s c o s i t y 1 . 8 4 ( 0 . 2 2 ) - 5  ( 7 . 6 ) 0 . 0 0 0 1 - 4  ( 1 2 . 8 ) 0 . 0 0 9 0 . 3
O s t e o c a l c i n  ® 7 . 1  ( 3 . 8 ) 1 5 ( 5 3 ) 0 . 0 2 1 8 ( 7 7 ) 0 . 0 2 0 . 8
B o n e  A i k .  P h o s  * 1 5 ( 1 7 . 4 ) 3 2  ( 1 1 6 . 6 ) 0 . 0 0 6 1 2  ( 1 4 4 ) 0 . 3 0 . 1 9
%  B o n e  A i k  P h o s * 1 6 . 2  ( 1 6 . 9 ) 4 6  ( 1 3 9 ) 0 . 0 0 1 1 8 . 6  ( 1 7 4 ) 0 . 4 0 . 3 8
U r i n a r y
P y r i d i n o l / c r e a t i n i n e
- 1 6 . 6  ( 1 1 2 ) 0 . 6 6 - 2 5 . 6 ( 1 4 8 ) 0 . 7 9 0 . 3 2
Note: ‘ Comparison with baseline value, “ Comparison of one year value with two year 
value, ® Total number of swollen joints in hands, ® Total number of tender joints in hands, 
@ nanograms per ml, *  units per litre. Percentage of bone isoenzyme in total alkaline 
phosphatase.
Rate Of Change In Hand BMC Over Two Years In Patients
Both male and female patients lost significant amount of hand BMC (Table 5, Figure 3) 
over two year period despite improvement in the parameters of disease activity. For 
males, the percent change in hand BMC (median (IQR)) compared to baseline result 
was: at six months -6 (7.3), at 12 months -4.8 (7.5), at 18 months -9 (9.1) and at 24 
months -4.8 (8.2) and for females it was: at six months -2.6 (5.7), at 12 months -3.5 
(10.5), at 18 months -7.1 (8.2) and at 24 months -6.5 (13.7). The comparison of results 
at 18 months with those at 24 months showed that female patients had regained 0.7 
(7.6) percent but male patients had lost 0.1 (7.3) percent hand BMC over the last six 
months, however these changes did not reach statistical significance.
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Table 5: Percent Changes (From Baseline) In Hand BMC In Patients With Early 
Rheumatoid Arthritis Over Two Years. Non-parametric Wilcoxon matched pairs test,
median (IQR).
P a i r e d  D i f f e r e n c e s B a s e l i n e P e r c e n t P * P e r c e n t P * P * *
I n  V a r i a b l e s V a l u e  I n  
G r a m s
C h a n g e  A t  
O n e  Y e a r
V a l u e C h a n g e  A t  
T w o  Y e a r s
V a l u e V a l u e
T o t a l  G r o u p 3 4 . 3  ( 1 5 . 1 ) - 4 . 6 5  ( 8 . 5 ) 0 . 0 0 0 1 - 6 . 4  ( 1 1 . 2 ) 0 . 0 0 0 0 0 . 0 2
M a l e s 4 3 . 5  ( 7 . 2 7 ) - 4 . 8  ( 7 . 5 ) 0 . 0 0 5 - 4 . 8  ( 8 . 2 ) 0 . 0 0 1 0 . 0 8
A l l  F e m a l e s 2 8 . 7  ( 5 . 7 ) - 3 . 5  ( 1 0 . 5 ) 0 . 0 0 9 - 6 . 5  ( 1 3 . 7 ) 0 . 0 0 2 0 . 1
P r e - M e n o p a u s a l
F e m a l e s
3 4 . 0  ( 6 . 6 ) - 4 . 6  ( 8 . 2 ) 0 . 1 - 6 . 3  ( 6 . 9 ) 0 . 0 3 0 . 7
P o s t - M e n o p a u s a l
F e m a l e s
2 7 . 7  ( 4 . 5 ) - 3 . 2  ( 1 1 . 3 ) 0 . 0 4 - 8 . 9  ( 1 4 . 2 ) 0 . 0 2 0 . 2
Note: ‘ Comparison with baseline value, “ Comparison of one year and two year values.
Changes In The Biochemical Parameters Of Bone Metabolism
There were significant increases in the serum levels of osteocalcin (p=0.02) and bone 
specific alkaline phosphatase (p=0.006, Table 3, Figure 4) in the first year but no 
significant changes over the second year. There was a significant increase in the 
percentage of bone isoenzyme in total alkaline phosphatase over the first year (p=0.001) 
and a similar trend over the second year (p=0.05). Throughout the two year period, 
urinary excretion of pyridinoline/creatinine (Pyd/Cr) and deoxy-pyridinoline/creatinine 
(Dpd/Cr) remained significantly elevated compared to normal ranges in females (for 
Pyd/Cr at 12 months p=0.006, at 24 months p=0.008; for Dpd/Cr at 12 months p=0.02, at 
24 months p=0.0009) but only for the first year in males (at 12 months, Pyd/Cr p=0.003 
and Dpd/Cr p=0.02). Compared to baseline results, however there was no significant 
change in either Pyd/Cr or Dpd/Cr excretion in male or female patients.
These biochemical parameters of bone metabolism however did not correlate with loss of 
hand BMC.
Hand BMC Correlations With Other Parameters Of Disease Activity And Severity
Over the two year study period, the percent annual loss of hand BMC correlated with 
mean number of swollen joints in the whole body (r=0.35, p=0.02), mean plasma 
viscosity (r=0.33, p=0.02), mean CRP (r=0.31, p=0.04) and mean number of swollen
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joints in both hands (r=0.3, p=0.04). The percent annual loss of hand BMC also 
correlated with percent increase in Larsen score (r=0.36, p=0.03).
Effect Of Menopause On Hand BMC
To investigate whether menopausal status affected the hand BMC at the baseline and its 
rate of loss over one year, analysis of covariance (ANCOVA) was used with presence of 
rheumatoid arthritis and menopause as two separate risk factors after correcting for 
confounders like age, height and weight.
In female patients with early RA, menopausal status (p=0.0001), but not the presence of 
disease (p=0.1), was the important determinant of hand BMC at baseline but, presence 
of rheumatoid arthritis (p=0.03) and not the menopausal status (p=0.2) was the sole 
determinant for the rate of loss of hand BMC.
In summary therefore, presence of rheumatoid arthritis is the sole determinant of the 
rapid loss of hand BMC in females with early RA.
COMPARISON BETWEEN CONTROLS. EARLY AND LATE RA GROUPS: CHANGES 
IN DOMINANT HAND BMC OVER ONE YEAR
We compared the changes in the dominant hand BMC in the normal volunteer control 
group (Chapter 4) and in the established RA group (“Late RA”, Chapter 5) over one year 
period with the similar changes in the “Early RA” group At baseline, there was no 
significant difference in the hand BMC in males in early and late RA groups after 
correcting for age (p=0.1). The rate of loss of hand BMC in males in the early RA group 
however was significantly greater than in the males from late RA group (p=0.01, Table 6, 
Figure 5) after correcting for age.
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Table 6: Percent Change In Dominant Hand BMC Over One Year In Controls And In
Patients With RA








Males 17 -5.26 11.49 0.007
Females 25 -2.14 10.1 0.03
Note: *p value refers to the paired differences between hand BMC at entry and at one 
year by Wilcoxon Matched Pairs Test.
Female patients from the late RA group had significantly lower hand BMC than female 
patients in the early RA group after correcting for height, weight and age (at entry 
p=0.0004 and at one year p=0.01 .Table 5, Figure 5). Females in the early RA group lost 
more bone than the females in the late RA group, but this difference in the rate of loss of 



















1. At initial assessment, male and post-menopausal female patients with early RA had 
significantly reduced hand bone mass as compared to normal volunteers.
2. Patients with early RA lost hand BMC progressively over eighteen months despite 
clinical improvement.
3. This bone loss correlated with mean values of number of swollen joints in body, 
number of swollen joints in hands, plasma viscosity and the CRP.
4. The biochemical markers of bone resorption (pyridinoline cross-links) were increased 
in patients at the start and remained increased throughout the study period.
5. The biochemical markers of bone formation were increased over the first year.
6. These findings suggest that the clinical improvement as shown by the reduction in 
the disease activity, combined with the increased osteoblastic activity led to 
stabilization of the hand bone mass at two years.
7. In female patients with early RA, the presence of the disease (but not the 
menopausal status) was the sole determinant of the loss of hand BMC.
8. The annual rate of loss of hand bone mass was greater in patients with early RA 
when compared to patients with late RA.
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List of Figures
Figure 1A and 1B: Measurement of hand bone mineral content (BMC) in a patient with 
early RA at entry (1A) and at 12 months (1B). Note the loss of 4.6 grams (9.6%) in hand 
BMC over one year period.
Figure 2: Changes in disease parameters in patients with RA over two years.
Figure 3: Changes in hand BMC in patients with RA over two year period. Note: M =
Males, Pre = Premenopausal Females, Post = Postmenopausal Females.
Figure 4: Changes in biochemical parameters of bone metabolism in patients with RA 
over two year period.
Figure 5: Changes in hand BMC over one year in controls and patients. Note: 1 = Male 
Volunteers, 2 = Male Patients: Early RA, 3 = Male Patients: Late RA, 4 = Female
Volunteers, 5 = Female Patients: Early RA and 6 = Female Patients: Late RA.
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Figure 3: Hand position: flat.
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CHANGE IN HAND BMC OVER ONE YEAR
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DISCUSSION AND CONCLUSIONS
100
We have developed a reproducible method of measuring hand bone mineral content 
using dual energy x-ray absorptiometry, by modifying the existing protocol of measuring 
BMC in the spine.
When scanning the spine, the greater bulk of the soft tissue "hardens" the x-ray beam by 
removing the lower energy x-rays. The Hologic QDR 1000 dual energy x-ray 
absorptiometer is therefore dependent on the soft tissue thickness (STT) and is 
accurate and precise to measure the BMC in the spine at that level of x-ray beam 
hardness. The hand has a much smaller amount of soft tissue compared to the spine 
and hence to get accurate and precise results for measurement of hand BMC, the 
Hologic spine protocol had to be altered.
Pye et al (1990) described a method of scanning the hand to overcome the problem of 
the dependency of spine protocol on the soft tissue thickness. Their approach was to 
artificially move the hand bone mass and the soft tissue towards a region where the 
response would be less sensitive to the STT. They suggested to use a perspex 
aluminium plate for this purpose. This plate can compensate for the smaller tissue bulk 
found in the hand so as to increase the hardness of the x-ray beam to match that when 
scanning the spine. We assessed three protocols of hand bone densitometry, two of 
which did not use such a plate. However, these were found to be less precise when 
dealing with an osteoporotic hand. We therefore decided to use a plate of 29 mm 
thickness (7mm aluminium and 22 mm of perspex) which was found to be adequate for 
our machine (Protocol 1), though further experiments are required to design an optimum 
thickness plate which can be used on other machines.. Use of this plate reduced the 
accuracy as the results were consistently higher than the ashed weight. We however 
think that this is unlikely to cause a major problem in clinical practice, as change in hand 
BMC in longitudinal studies is going to be more important than the absolute value in an 
individual.
Calibration factors Q1, Q2 and Q3 are used to obtain a linear relationship between the 
actual amount of bone mineral and the result obtained by the DXA scan. These exist for 
the hip and spine but had to be calculated for the smaller bones of the hand. This was 
achieved by scanning an aluminium step wedge of known different thickness to mimic 
the different quantities of bone mineral within the small bones of the hand.
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Our method gave a measurement of hand BMC with a coefficient of variation of 2.3% 
with no additional inter-observer variation. As RA progresses, the consequent deformity 
results in a change in hand position. However, our reproducibility data shows that the 
precision of measuring total hand BMC was unchanged by the hand position. In 
contrast, BMD measurement depends on the area of the hand, which is altered by 
changing the hand position. Bone mineral content rather than bone mineral density 
should therefore be used for further longitudinal studies of the hand. This method takes 
10 minutes to scan one hand and a further 3 to 4 minutes to analyze it. All volunteers 
found the position of scanning quite comfortable. Patients with rheumatoid involvement 
of the shoulder with poor abduction found most difficulty positioning the hand on the 
machine but by adjusting the height of the chair they were able to find a satisfactory 
position for the duration of the scan.
Most of the analysis is automated with automatic delineation of the bones of the hand 
minimizing operator interaction and consequent variability. Change of hand position 
from flat to slightly flexed, simulating rheumatoid hand, did not alter the precision of Che 
measured hand BMC whereas a slight change in hand position can alter the assessment 
of joint space and erosions by plain radiographs (Brower 1990) which are conventionally 
used to monitor progression of RA. This method is therefore more objective than plain 
radiographs and avoids the subjectivity of x-ray scoring methods.
Hand BMC correlated in both sexes with indices of body size like forearm span, height, 
weight and hand volume. In volunteers it did not correlate with age in contrast to the 
BMC in spine or hip, which is known to reduce after menopause in females. This 
apparent difference in age related changes to other parts of the skeleton could be 
explained by the "regenerative changes" of osteoarthritis. Some of the classical changes 
of osteoarthritis include sclerosis of bone margins and development of new bone such as 
the Heberden's and Bouchard's nodes in hands. In DEXA measurements of the spine, 
the osteophyte formations coupled with the sclerotic changes are known to give higher 
results of BMC (Masud et al 1993). None of our volunteers had clinical evidence of 
osteoarthritis but asymptomatic osteoarthritis in hands is quite common with advancing 
age. We did not however perform plain hand x-rays of our volunteers.
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Exercise is known to stimulate bone growth (Bouxsein et al 1994) but our study found no 
difference between the BMC of the dominant and non-dominant hand in the volunteers. 
They were not however manual workers but principally hospital staff.
Radiological changes in the hands have been used for many years to assess the 
outcome of RA but significant problems exist in quantifying them (Brower 1990). The 
global scoring method of Larsen (Larsen et al 1977), where a single score is given for all 
the radiological abnormalities in the joint under consideration, and the detailed scoring 
method of Sharp (Sharp et al 1985), where a separate score is given to each radiological 
abnormality in the joint concerned, have the problem of poor sensitivity to monitor 
change. Change of hand position can alter the assessment of joint space and erosions 
by plain radiographs (Brower 1990). These methods can therefore be either imprecise 
and coarse or too cumbersome and time consuming. They require interested and 
trained observers. Microfocal radiographs and MRI scans can detect changes earlier 
than conventional radiography, though the changes in microfocal radiographs are not 
quantitative and in the case of MRI, the costs could be prohibitive. In contrast, 
measurement of hand BMC is quantitative, reproducible even on changing hand position 
and automated to avoid the observer error. It is much cheaper than an MRI scan and 
can be performed on machines easily available in district general hospitals.
The subject of generalized osteoporosis in inflammatory arthritis has been extensively 
studied though most of the studies have measured bone density at the lumber spine 
and femoral neck to examine the effect of inflammation at these distant sites (Bhalla et al 
1992, Laan et al 1992, Sambrook et al 1985, Gough et al 1991). As the hip is not always 
and lumbar vertebrae are very rarely involved directly by the disease process in RA, the 
changes in BMC at these sites largely indicate the generalized changes in bone 
metabolism caused by an inflammatory disorder. Our method however is not aimed at 
only assessing these more generalized changes but principally assessing what is 
happening at a site of widespread disease involvement and of functional impairment. 
The hand with its multiple joints and periarticular bone involvement in RA combined with 
the functional effects of disease on its usage may act as a site for composite 
assessment of overall disease progression by measurement of the bone mineral content.
After correcting for physical size, patients (male and female) with early RA had on 
average 7.6% lower hand bone mass even at entry as compared to controls and on 
average lost a further 2.35% hand BMC over one year. Rheumatoid arthritis is known to
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cause a generalized skeletal effect with bone loss in femoral neck and lumbar spine 
(Shenstone et al 1994, Gough et al 1994) though a recent cross-sectional study has 
shown that changes in hand bone mass are more dramatic than changes at other sites 
(Peel 1994), with a reduction in hand bone mineral density of 23% as compared to 16% 
at the femoral neck and 11% at the lumbar spine (Peel et al 1994). The loss of hand 
bone mass in patients with RA therefore appear to be a combined result of the 
generalized plus local effects of the disease.
There are several possibilities why patients with RA had significantly lower hand BMC. 
Certain cytokines like Interleukin 1, Interleukin 6 and tumour necrosis factor a which are 
potent stimulators of bone resorption, have been implicated in the juxta-articular as well 
as generalized bone loss in rheumatoid arthritis (Bhalla et al 1993). Treatment with 
corticosteroids and reduced mobility have also been suggested as possible important 
factors (Laan et al 1992, Riis et al 1985) but in this study we could not find any 
appreciable effect of steroid use although the numbers were small. Menopausal status 
appears to be a co-factor for loss of hand BMC in postmenopausal females with RA of 
longer duration but the rapid loss of hand BMC in early RA is independent of the 
menopausal status. Hormone replacement therapy (HRT) has recently been shown to 
increase spinal bone density and maintain femoral bone density (Hall et al 1994) in 
patients with RA. It would be interesting to see whether HRT has a similar protective role 
on hand bone loss.
In patients with RA, hand BMC correlated variably with parameters of disease severity 
but not with parameters of disease activity. Hand BMC did not show significant 
correlation with Ritchie Index, swollen joint count or duration of early morning stiffness, 
loose indicators of ongoing inflammatory disease process. Correlation was however 
better with disease duration and with the radiological scores. It is not surprising to find 
the poor correlation between the measures of disease activity with a single measurement 
of hand BMC as logically one would expect hand BMC to be an outcome measure and 
the better correlation with the disease duration and radiological measures of disease 
outcome might be expected.
Our longitudinal data demonstrates that the most rapid rate of loss of hand bone density 
occurs very early in the disease (over one year 4.88% in early RA males and 2.14% in 
early RA females). Studies looking at the bone density in the lumbar spine and femoral 
neck of patients with RA have also shown significant bone loss very early in the disease
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(Shenstone et al 1994, Gough et al 1994). Long term follow-up in these patients is 
needed to see whether the loss of hand BMC correlates with future loss of function and 
poor outcome. The annual rate of change of hand BMC in patients with early RA varied 
from +11% to -22% and this correlated with baseline CRP but did not correlate with 
indicators of hand function such as grip strength. This loss occured despite 
improvement in other validated measures of disease activity indicating that eventhough 
the current treatment of RA is successful in improving symptoms and markers of 
inflammation, it may not be very effective in controlling the early loss of bone. However, 
there appears to be a lag period of about 18 months before these benefits are reflected 
in hand BMC measurement. The data from the second year of our prospective 
longitudinal bone densitometry study showed that by suppressing the disease activity 
effectively the process of bone loss can be halted. We therefore think that our study 
provides yet another strong reason to intervene as early as possible to prevent the early 
rapid bone loss in hands in patients with RA.
Urinary collgen cross-link excretion remained high over most of the time in our patients 
indicating continued degradation of collagen from bone and cartilage. However, the 
biochemical markers of osteoblastic activity (osteocalcin and bone isoenzyme of alkaline 
phosphatase) showed significant increases in the first year of the study and in case of 
bone alkaline phosphatase, remained elevated even in the second year (although did not 
reach statistical significance due to small numbers at the end of two years). It therefore 
appears that the compensatory osteoblastic reaction could be responsible for 
stabilisation of the hand BMC later in the disease course. Previous studies on serum 
osteocalcin (OC) in patients with RA have demonstrated variable results (Sambrook et al 
1985, Weisman et al 1986, Ekenstam et al 1986, Magaro et al 1989) but two other 
studies have shown raised OC levels in patients with RA (Magaro et al 1989, Marhoffer 
et al 1991) which were found to correlate with the disease activity.
Larsen score and number of erosions also worsened significantly in our study and the 
increase in Larsen score correlated with loss in hand BMC. However, as explained 
above, the Larsen's method of scoring radiographs is cumbersome, time consuming and 
needs interested and trained observers. In inexperienced hands, early radiographic 
changes can be subjective, resulting in poor reproducibility. Nearly two decades after it 
was first described, it has therefore remained a research tool. Hand BMC measurement 
has the advantage of being quick, precise and has no inter-observer variability. It also 
has the potential to be performed routinely on standard equipment available in many 
hospitals. Our experience with hand BMC measurement in patients with RA shows that
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t h i s  t e c h n i q u e  c o u l d  b r i d g e  t h e  g a p  b e t w e e n  a  ' p r o c e s s '  a n d  a n  ' o u t c o m e '  v a r i a b l e  a s  it 
s h a r e s  p r o p e r t i e s  o f  b o t h .
H a n d  b o n e  d e n s i t o m e t r y  i s  a n  a c c u r a t e ,  r e p r o d u c i b l e  a n d  s e n s i t i v e  q u a n t i t a t i v e  m e a s u r e  
o f  b o n y  c h a n g e s  i n  t h e  h a n d  t h a t  h a s  t h e  p o t e n t i a l  t o  b e  u s e d  a s  a  g o l d  s t a n d a r d  
o u t c o m e  m e a s u r e  i n  e a r l y  s t a g e s  o f  r h e u m a t o i d  a r t h r i t i s ,  t h e  v e r y  c r u c i a l  t i m e  w h e n  
m a x i m u m  d a m a g e  t o  t h e  b o n e s  i s  d o n e .  It a l s o  o p e n s  u p  n e w  p o s s i b i l i t i e s  o f  e v a l u a t i n g  
n e w e r  t h e r a p i e s  a i m e d  t o  p r e v e n t  t h e s e  e a r l y  b o n e  c h a n g e s  a n d  h a n d  b o n e  
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